Skip to main content
Psychedex
Sources
37
12 strong · 17 moderate · 8 weak

Studies and references cited across this article, graded by evidence strength.

Claims checked
65
41verified24inconclusive

Inconclusive means the cited source neither confirms nor refutes the claim — a lower-confidence badge, not an error.

Generated
May 12, 2026 · pipeline-v5
Values approved
71/71 (100%)

Data points an editor reviewed and accepted for publication.

01

Value Provenance

Dosing

oraltrace

FieldPublishedAI ProposedConfidence
Threshold8 mg8 mghigh
Low8–15 mg8–15 mghigh
Common15–37.5 mg15–37.5 mghigh
Strong37.5–37.5 mg37.5–37.5 mghigh
Heavy——high
Editorial

Dose tiers derived from FDA prescribing information: Lomaira 8 mg (threshold/light), Adipex-P 15–37.5 mg (common range), 37.5 mg (maximum FDA-approved single daily dose = strong). Heavy tier omitted as numeric value because no controlled data exist above 37.5 mg and FDA label explicitly warns against exceeding this dose. Bioavailability ~100% per INCHEM monograph and FDA label.

Reasoning

Dose tiers derived from FDA prescribing information: Lomaira 8 mg (threshold/light), Adipex-P 15–37.5 mg (common range), 37.5 mg (maximum FDA-approved single daily dose = strong). Heavy tier omitted as numeric value because no controlled data exist above 37.5 mg and FDA label explicitly warns against exceeding this dose. Bioavailability ~100% per INCHEM monograph and FDA label.

Evidence basis: controlled_human_study

Duration

oral

FieldPublishedAI ProposedConfidence
Onsettrace30–60 minutes30–60 minuteslow
Editorial

Inferred from Tmax of 1–3 hours for IR HCl formulation. Onset estimated as first 30–60 minutes before perceptible subjective effects emerge. No published controlled pharmacodynamic onset study exists for phentermine.

Reasoning

Inferred from Tmax of 1–3 hours for IR HCl formulation. Onset estimated as first 30–60 minutes before perceptible subjective effects emerge. No published controlled pharmacodynamic onset study exists for phentermine.

Evidence basis: structural_analogy

Come uptrace30–120 minutes30–120 minuteslow
Editorial

Estimated from Tmax (1–3h) and pharmacodynamic lag. Come-up spans from first noticeable effects to approaching peak intensity. No published PD duration study.

Reasoning

Estimated from Tmax (1–3h) and pharmacodynamic lag. Come-up spans from first noticeable effects to approaching peak intensity. No published PD duration study.

Evidence basis: structural_analogy

Peaktrace2–6 hours2–6 hourslow
Editorial

Work-notes estimate peak at 2–6 hours based on Tmax 1–3h for IR formulation plus pharmacodynamic lag. No controlled pharmacodynamic study directly measured peak duration.

Reasoning

Work-notes estimate peak at 2–6 hours based on Tmax 1–3h for IR formulation plus pharmacodynamic lag. No controlled pharmacodynamic study directly measured peak duration.

Evidence basis: structural_analogy

Offsettrace6–12 hours6–12 hourslow
Editorial

Estimated from half-life context (16–31h). Offset represents declining subjective intensity from peak toward baseline. The long elimination half-life produces an extended offset phase. No published PD offset study.

Reasoning

Estimated from half-life context (16–31h). Offset represents declining subjective intensity from peak toward baseline. The long elimination half-life produces an extended offset phase. No published PD offset study.

Evidence basis: structural_analogy

Totaltrace8–14 hours8–14 hourslow
Editorial

Work-notes estimate total subjective duration at 8–14 hours, inferred from pharmacokinetics. This represents the period of perceptible subjective effects, not the full pharmacological half-life. No published controlled PD duration study exists.

Reasoning

Work-notes estimate total subjective duration at 8–14 hours, inferred from pharmacokinetics. This represents the period of perceptible subjective effects, not the full pharmacological half-life. No published controlled PD duration study exists.

Evidence basis: structural_analogy

After effectstrace12–24 hours12–24 hourslow
Editorial

Work-notes estimate 12–24 hours of residual sympathomimetic effects given the 16–31 hour half-life. Residual wakefulness and potential insomnia persist well beyond subjective stimulant effects.

Reasoning

Work-notes estimate 12–24 hours of residual sympathomimetic effects given the 16–31 hour half-life. Residual wakefulness and potential insomnia persist well beyond subjective stimulant effects.

Evidence basis: structural_analogy

Safety

Toxicity Profiletrace

FieldPublishedAI ProposedConfidence
Acutemoderatemoderatemedium
Chronicmoderatemoderatemedium
Organs Affectedcardiovascular, central nervous system, renal, thermoregulatorycardiovascular, central nervous system, renal, thermoregulatorymedium
Editorial

Work-notes assign moderate acute and moderate chronic toxicity. Evidence base is FDA prescribing label adverse events, INCHEM monograph (WHO/IPCS), population overdose data (Hall 2023), and single case report of monotherapy pulmonary hypertension (Bang 2010). No human LD50 exists. Fatal overdoses are predominantly polydrug. Confidence medium because chronic cardiovascular risk is incompletely characterised pending LEAP trial completion.

Reasoning

Work-notes assign moderate acute and moderate chronic toxicity. Evidence base is FDA prescribing label adverse events, INCHEM monograph (WHO/IPCS), population overdose data (Hall 2023), and single case report of monotherapy pulmonary hypertension (Bang 2010). No human LD50 exists. Fatal overdoses are predominantly polydrug. Confidence medium because chronic cardiovascular risk is incompletely characterised pending LEAP trial completion.

Evidence basis: published_case_series

Dependence Profiletrace

FieldPublishedAI ProposedConfidence
Physicalnegligiblenegligiblehigh
Psychologicallowlowhigh
Compulsive Redosinglowlowhigh
Dose Escalationlowlowhigh
Editorial

Work-notes assign negligible physical dependence and low psychological dependence with high confidence. The Hendricks & Greenway (2011) abrupt cessation study (n=35) provides direct evidence of absent withdrawal. The Jasinski (2008) abuse liability study confirms recognisable but attenuated stimulant subjective effects. FDA Schedule IV classification reflects recognised but low abuse potential.

Reasoning

Work-notes assign negligible physical dependence and low psychological dependence with high confidence. The Hendricks & Greenway (2011) abrupt cessation study (n=35) provides direct evidence of absent withdrawal. The Jasinski (2008) abuse liability study confirms recognisable but attenuated stimulant subjective effects. FDA Schedule IV classification reflects recognised but low abuse potential.

Evidence basis: controlled_human_study

Withdrawal Profiletrace

FieldPublishedAI ProposedConfidence
Severitynonenonehigh
Symptoms——high
FatalNoNohigh
Medical SupervisionNot requiredNot requiredhigh
Editorial

Hendricks & Greenway (2011) directly studied abrupt cessation of long-term phentermine in 35 patients. Withdrawal severity scores were not significantly different from drug-naïve controls. Cravings were entirely absent. The study explicitly concluded that phentermine cessation does not produce amphetamine-like withdrawal.

Reasoning

Hendricks & Greenway (2011) directly studied abrupt cessation of long-term phentermine in 35 patients. Withdrawal severity scores were not significantly different from drug-naïve controls. Cravings were entirely absent. The study explicitly concluded that phentermine cessation does not produce amphetamine-like withdrawal.

Evidence basis: controlled_human_study

Tolerance Profiletrace

FieldPublishedAI ProposedConfidence
Builduprapidrapidmedium
Half-life——medium
Full Reset——medium
Cross-tolerancesamphetamine, methamphetamine, MDMAamphetamine, methamphetamine, MDMAmedium
Editorial

Work-notes assign rapid buildup (weeks) with medium confidence. Tolerance existence is high-confidence from FDA label; mechanism and reset timing are low-confidence. Cross-tolerance entries are structural-analogy inferences (work-notes explicitly flag these as class-extrapolated).

Reasoning

Work-notes assign rapid buildup (weeks) with medium confidence. Tolerance existence is high-confidence from FDA label; mechanism and reset timing are low-confidence. Cross-tolerance entries are structural-analogy inferences (work-notes explicitly flag these as class-extrapolated).

Evidence basis: controlled_human_study

Effects & Profile

Contraindications

FieldPublishedAI ProposedConfidence
other MAOI use (within 14 days)traceabsoluteabsolutehigh
Editorial

FDA prescribing information lists MAOI use within 14 days as an absolute contraindication. Mechanism is well-established pharmacologically. Work-notes list this as the first contraindication entry.

Reasoning

FDA prescribing information lists MAOI use within 14 days as an absolute contraindication. Mechanism is well-established pharmacologically. Work-notes list this as the first contraindication entry.

cardiovascular Cardiovascular diseasetraceabsoluteabsolutehigh
Editorial

FDA prescribing information explicitly lists all five cardiovascular conditions as absolute contraindications. Cardiovascular toxicity is the principal safety concern documented across the article prose and research output.

Reasoning

FDA prescribing information explicitly lists all five cardiovascular conditions as absolute contraindications. Cardiovascular toxicity is the principal safety concern documented across the article prose and research output.

metabolic Hyperthyroidismtraceabsoluteabsolutehigh
Editorial

Listed in FDA prescribing information as absolute contraindication. Work-notes include hyperthyroidism with high confidence.

Reasoning

Listed in FDA prescribing information as absolute contraindication. Work-notes include hyperthyroidism with high confidence.

other Glaucomatraceabsoluteabsolutehigh
Editorial

FDA prescribing information lists glaucoma as absolute contraindication. Mechanism is class-level for all sympathomimetic amines.

Reasoning

FDA prescribing information lists glaucoma as absolute contraindication. Mechanism is class-level for all sympathomimetic amines.

psychiatric Agitated statestraceabsoluteabsolutehigh
Editorial

FDA prescribing information lists agitated states as absolute contraindication. Work-notes confirm with high confidence.

Reasoning

FDA prescribing information lists agitated states as absolute contraindication. Work-notes confirm with high confidence.

psychiatric History of drug abusetraceabsoluteabsolutehigh
Editorial

FDA prescribing information lists drug abuse history as absolute contraindication. Abuse liability study confirms recognisable stimulant effects in abusers.

Reasoning

FDA prescribing information lists drug abuse history as absolute contraindication. Abuse liability study confirms recognisable stimulant effects in abusers.

immunological Sympathomimetic amine hypersensitivitytraceabsoluteabsolutehigh
Editorial

FDA prescribing information lists known hypersensitivity to sympathomimetic amines as absolute contraindication. Work-notes confirm.

Reasoning

FDA prescribing information lists known hypersensitivity to sympathomimetic amines as absolute contraindication. Work-notes confirm.

pregnancy breastfeeding Pregnancytraceabsoluteabsolutehigh
Editorial

FDA prescribing information contraindicates use in pregnancy. Work-notes flag pregnancy monotherapy risk as safety_data_unverified due to absence of controlled data.

Reasoning

FDA prescribing information contraindicates use in pregnancy. Work-notes flag pregnancy monotherapy risk as safety_data_unverified due to absence of controlled data.

pregnancy breastfeeding Lactationtraceabsoluteabsolutemedium
Editorial

FDA prescribing information contraindicates use during nursing. Work-notes assign medium confidence due to uncharacterised breast milk excretion rather than documented harm.

Reasoning

FDA prescribing information contraindicates use during nursing. Work-notes assign medium confidence due to uncharacterised breast milk excretion rather than documented harm.

Timeline Phases

oral

FieldPublishedAI ProposedConfidence
Onsettrace1800–3600 sec(i=0.10)1800–3600 sec(i=0.10)low
Editorial

Duration estimates are pharmacokinetic inferences from Tmax (1–3h for IR HCl salt) and half-life (16–31h). No published controlled pharmacodynamic duration study exists for individual phentermine doses. Work-notes explicitly flag duration data as PK-inferred with low confidence. Phase mapping follows work-notes: onset/come_up/peak/plateau/resolution/afterglow. The long half-life produces an unusually extended plateau and afterglow relative to most stimulants.

Reasoning

Duration estimates are pharmacokinetic inferences from Tmax (1–3h for IR HCl salt) and half-life (16–31h). No published controlled pharmacodynamic duration study exists for individual phentermine doses. Work-notes explicitly flag duration data as PK-inferred with low confidence. Phase mapping follows work-notes: onset/come_up/peak/plateau/resolution/afterglow. The long half-life produces an unusually extended plateau and afterglow relative to most stimulants.

Evidence basis: structural_analogy

Come uptrace1800–5400 sec(i=0.40)1800–5400 sec(i=0.40)low
Editorial

Duration estimates are pharmacokinetic inferences from Tmax (1–3h for IR HCl salt) and half-life (16–31h). No published controlled pharmacodynamic duration study exists for individual phentermine doses. Work-notes explicitly flag duration data as PK-inferred with low confidence. Phase mapping follows work-notes: onset/come_up/peak/plateau/resolution/afterglow. The long half-life produces an unusually extended plateau and afterglow relative to most stimulants.

Reasoning

Duration estimates are pharmacokinetic inferences from Tmax (1–3h for IR HCl salt) and half-life (16–31h). No published controlled pharmacodynamic duration study exists for individual phentermine doses. Work-notes explicitly flag duration data as PK-inferred with low confidence. Phase mapping follows work-notes: onset/come_up/peak/plateau/resolution/afterglow. The long half-life produces an unusually extended plateau and afterglow relative to most stimulants.

Evidence basis: structural_analogy

Peaktrace7200–14400 sec(i=1.00)7200–14400 sec(i=1.00)low
Editorial

Duration estimates are pharmacokinetic inferences from Tmax (1–3h for IR HCl salt) and half-life (16–31h). No published controlled pharmacodynamic duration study exists for individual phentermine doses. Work-notes explicitly flag duration data as PK-inferred with low confidence. Phase mapping follows work-notes: onset/come_up/peak/plateau/resolution/afterglow. The long half-life produces an unusually extended plateau and afterglow relative to most stimulants.

Reasoning

Duration estimates are pharmacokinetic inferences from Tmax (1–3h for IR HCl salt) and half-life (16–31h). No published controlled pharmacodynamic duration study exists for individual phentermine doses. Work-notes explicitly flag duration data as PK-inferred with low confidence. Phase mapping follows work-notes: onset/come_up/peak/plateau/resolution/afterglow. The long half-life produces an unusually extended plateau and afterglow relative to most stimulants.

Evidence basis: structural_analogy

Plateautrace10800–18000 sec(i=0.70)10800–18000 sec(i=0.70)low
Editorial

Duration estimates are pharmacokinetic inferences from Tmax (1–3h for IR HCl salt) and half-life (16–31h). No published controlled pharmacodynamic duration study exists for individual phentermine doses. Work-notes explicitly flag duration data as PK-inferred with low confidence. Phase mapping follows work-notes: onset/come_up/peak/plateau/resolution/afterglow. The long half-life produces an unusually extended plateau and afterglow relative to most stimulants.

Reasoning

Duration estimates are pharmacokinetic inferences from Tmax (1–3h for IR HCl salt) and half-life (16–31h). No published controlled pharmacodynamic duration study exists for individual phentermine doses. Work-notes explicitly flag duration data as PK-inferred with low confidence. Phase mapping follows work-notes: onset/come_up/peak/plateau/resolution/afterglow. The long half-life produces an unusually extended plateau and afterglow relative to most stimulants.

Evidence basis: structural_analogy

Resolutiontrace10800–14400 sec(i=0.30)10800–14400 sec(i=0.30)low
Editorial

Duration estimates are pharmacokinetic inferences from Tmax (1–3h for IR HCl salt) and half-life (16–31h). No published controlled pharmacodynamic duration study exists for individual phentermine doses. Work-notes explicitly flag duration data as PK-inferred with low confidence. Phase mapping follows work-notes: onset/come_up/peak/plateau/resolution/afterglow. The long half-life produces an unusually extended plateau and afterglow relative to most stimulants.

Reasoning

Duration estimates are pharmacokinetic inferences from Tmax (1–3h for IR HCl salt) and half-life (16–31h). No published controlled pharmacodynamic duration study exists for individual phentermine doses. Work-notes explicitly flag duration data as PK-inferred with low confidence. Phase mapping follows work-notes: onset/come_up/peak/plateau/resolution/afterglow. The long half-life produces an unusually extended plateau and afterglow relative to most stimulants.

Evidence basis: structural_analogy

Afterglowtrace14400–36000 sec(i=0.10)14400–36000 sec(i=0.10)low
Editorial

Duration estimates are pharmacokinetic inferences from Tmax (1–3h for IR HCl salt) and half-life (16–31h). No published controlled pharmacodynamic duration study exists for individual phentermine doses. Work-notes explicitly flag duration data as PK-inferred with low confidence. Phase mapping follows work-notes: onset/come_up/peak/plateau/resolution/afterglow. The long half-life produces an unusually extended plateau and afterglow relative to most stimulants.

Reasoning

Duration estimates are pharmacokinetic inferences from Tmax (1–3h for IR HCl salt) and half-life (16–31h). No published controlled pharmacodynamic duration study exists for individual phentermine doses. Work-notes explicitly flag duration data as PK-inferred with low confidence. Phase mapping follows work-notes: onset/come_up/peak/plateau/resolution/afterglow. The long half-life produces an unusually extended plateau and afterglow relative to most stimulants.

Evidence basis: structural_analogy

Dose Tier Summaries

thresholdtrace
high

At 8 mg oral (the Lomaira low-dose formulation), subjective effects are minimal. A subtle increase in wakefulness and mild alertness may be noticeable, but appetite suppression is slight and cognitive changes are negligible. There is no euphoria or mood elevation at this level. Physical effects are correspondingly subtle: a faint increase in heart rate and blood pressure that most users will not perceive, mild dry mouth in some individuals, and a barely perceptible increase in body temperature. Stimulation is functional rather than felt. This dose represents the lowest FDA-approved unit, designed for three-times-daily dosing. Insomnia is unlikely unless taken in the evening. Tolerance develops within weeks even at this level.

Editorial

8 mg corresponds to the Lomaira formulation, the lowest FDA-approved dose. Work-notes specify threshold at 8 mg with minimal appetite suppression and mild wakefulness. Effects described are consistent with the pharmacological profile at sub-therapeutic single doses.

Reasoning

8 mg corresponds to the Lomaira formulation, the lowest FDA-approved dose. Work-notes specify threshold at 8 mg with minimal appetite suppression and mild wakefulness. Effects described are consistent with the pharmacological profile at sub-therapeutic single doses.

Evidence basis: controlled_human_study

lighttrace
high

At 8–15 mg oral, appetite suppression becomes noticeable — meals feel less compelling, and the drive to eat between meals diminishes. Wakefulness increases perceptibly, producing a sustained, low-grade alertness without the jitteriness of high-dose caffeine. Mild focus enhancement and motivation enhancement may be present but are subtle. Physically, heart rate rises slightly (typically 5–10 bpm), blood pressure may increase modestly, and dry mouth becomes more common. Restlessness is mild or absent. Stimulation is functional — more akin to sustained alertness than energetic arousal. Insomnia is possible if dosed in the afternoon or evening. The experience is dominated by appetite suppression rather than any pronounced cognitive or emotional shift.

Editorial

Work-notes specify 8–15 mg as the light range with noticeable appetite reduction, mild psychomotor activation, and slight cardiovascular increases. FDA prescribing information and clinical trial adverse event data support these effects at the lower end of the therapeutic range.

Reasoning

Work-notes specify 8–15 mg as the light range with noticeable appetite reduction, mild psychomotor activation, and slight cardiovascular increases. FDA prescribing information and clinical trial adverse event data support these effects at the lower end of the therapeutic range.

Evidence basis: controlled_human_study

commontrace
high

At 15–37.5 mg oral, the full therapeutic profile emerges. Appetite suppression is pronounced — hunger signals are substantially blunted, and caloric intake decreases meaningfully. Wakefulness is sustained throughout the day, and mild cognitive euphoria or mood brightening may be present, though far less intense than with amphetamine. Focus enhancement and motivation enhancement are noticeable but modest. Dry mouth is the most frequently reported physical effect. Stimulation is clear: elevated heart rate, mild blood pressure increase, and occasional restlessness or fidgetiness. Constipation occurs in a minority of users. Headache and trembling are possible but uncommon. Insomnia is likely if the dose is taken after midday. This is the standard clinical range — effects last 8–14 hours subjectively, with residual wakefulness extending further due to the 16–31 hour half-life. Tolerance to the anorectic effect typically develops within a few weeks of continuous use.

Editorial

Work-notes specify 15–37.5 mg as the common range producing full anorectic effect and sustained wakefulness. This maps directly to FDA-approved dosing (Adipex-P 15–37.5 mg/day). Adverse event frequencies from clinical trials and prescribing information inform the physical effect descriptions.

Reasoning

Work-notes specify 15–37.5 mg as the common range producing full anorectic effect and sustained wakefulness. This maps directly to FDA-approved dosing (Adipex-P 15–37.5 mg/day). Adverse event frequencies from clinical trials and prescribing information inform the physical effect descriptions.

Evidence basis: controlled_human_study

strongtrace
high

At 37.5 mg oral (the maximum FDA-approved single daily dose), appetite suppression is pronounced and sustained. Stimulation is clearly perceptible — heightened alertness, restlessness, and difficulty sitting still. Mild euphoria may occur, particularly in the first days of use before tolerance develops. Anxiety and irritability become more likely at this level. Cardiovascular effects are more prominent: elevated heart rate, noticeable blood pressure increase, and vasoconstriction producing cold extremities in some individuals. Dry mouth is very common. Insomnia is likely regardless of dosing time due to the long half-life. Trembling, headache, and excessive sweating are possible. This dose represents the FDA-approved ceiling. The prescribing label explicitly directs against exceeding 37.5 mg/day and instructs discontinuation rather than dose escalation when tolerance develops.

Editorial

Work-notes specify 37.5 mg as the strong tier — maximum FDA-approved dose with pronounced appetite suppression, insomnia, restlessness, and elevated cardiovascular parameters. Adverse event frequency data from clinical trials supports increased incidence of side effects at this dose level.

Reasoning

Work-notes specify 37.5 mg as the strong tier — maximum FDA-approved dose with pronounced appetite suppression, insomnia, restlessness, and elevated cardiovascular parameters. Adverse event frequency data from clinical trials supports increased incidence of side effects at this dose level.

Evidence basis: controlled_human_study

heavytrace
medium

Above 37.5 mg oral, dosing is supratherapeutic and unsupported by clinical evidence. The risk of sympathomimetic toxidrome escalates substantially: severe hypertension, tachycardia, arrhythmias, agitation, and hyperthermia become increasingly likely. Psychosis, delirium, and seizures are possible at high supratherapeutic doses. Physically, the sympathomimetic burden becomes dangerous: pronounced vasoconstriction, cardiac arrhythmias, muscle tension progressing to fasciculations or rhabdomyolysis, and hyperpyrexia. The cardiovascular risk profile at these doses is qualitatively different from therapeutic use. The FDA prescribing label explicitly warns against exceeding 37.5 mg/day. No controlled data exist for supratherapeutic doses. Blood concentration toxicity thresholds are highly variable (20–3,000 µg/L range documented), reflecting tolerance-dependent susceptibility.

Editorial

Work-notes specify >37.5 mg as heavy with escalating sympathomimetic toxidrome risk. No controlled dose-response data exist above 37.5 mg. Toxicity profile is inferred from overdose case series, the INCHEM monograph, and the sympathomimetic class toxidrome. Confidence medium due to absence of controlled supratherapeutic dose data.

Reasoning

Work-notes specify >37.5 mg as heavy with escalating sympathomimetic toxidrome risk. No controlled dose-response data exist above 37.5 mg. Toxicity profile is inferred from overdose case series, the INCHEM monograph, and the sympathomimetic class toxidrome. Confidence medium due to absence of controlled supratherapeutic dose data.

Evidence basis: published_case_series

02

History

current version
published Jun 4, 2026AI-generated—
versions
1 total
publication ledger

backfill Jun 4, 2026

Historical versions do not record which reviewer approved them; editorial accountability is recorded per value in the database and in the publication ledger going forward.

full version history suggest a correctioncontact@psychedex.org
03

Sources

12 strong · 17 moderate · 8 weak
  1. [1]
    weak
    Phentermine free base - CAS 122-09-8 chemical identity
    NIST/ChemSpider/PubChem · 2024
    linkno claims checked
  2. [2]
    moderate
    Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin
    Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, Partilla JS · 2001 · Synapse
    pubmed 110717077 claims checked3 verified4 inconclusive
  3. [3]
    weak
    Phentermine Hydrochloride Tablets (Adipex-P) Prescribing Information
    Gate Pharmaceuticals/Teva Pharmaceuticals · 2012
    linkno claims checked
  4. [4]
    weak
    Valvular heart disease associated with fenfluramine-phentermine
    Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Schaff HV · 1997 · New England Journal of Medicine
    pubmed 92714794 claims checked3 verified1 inconclusive
  5. [5]
    strong
    Noradrenergic and dopaminergic effects of (+)-amphetamine-like stimulants in the baboon Papio anubis
    Alexander M, Rothman RB, Baumann MH, et al. · 2005 · Synapse
    pubmed 157297396 claims checked4 verified2 inconclusive
  6. [6]
    moderate
    A study of abrupt phentermine cessation in patients in a weight management program
    Hendricks EJ, Greenway FL · 2011 · American Journal of Therapeutics
    doi.org/10.1097/mjt.0b013e3181d070d7pubmed 205926623 claims checked3 verified
  7. [7]
    weak
    Pulmonary hypertension associated with use of phentermine
    Bang WD, Kim JY, Yu HT, et al. · 2010 · Yonsei Medical Journal
    doi.org/10.3349/ymj.2010.51.6.pubmed 208790692 claims checked1 verified1 inconclusive
  8. [8]
    strong
    The long-term effectiveness of the anti-obesity medication phentermine (LEAP) trial: Rationale, design, and baseline characteristics
    Young CB, Rives E, Gudzune KA, et al. · 2026 · Contemporary Clinical Trials
    doi.org/10.1016/j.cct.2026.108219pubmed 415194312 claims checked2 verified
  9. [9]
    weak
    Phentermine (PIM 415) - INCHEM International Programme on Chemical Safety
    International Programme on Chemical Safety (WHO/IPCS) · 1999
    linkno claims checked
  10. [10]
    strong
    Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo
    Weintraub M, Sundaresan PR, Madan M, et al. · 1992 · Clinical Pharmacology and Therapeutics
    pubmed 15870721 claim checked1 verified
  11. [11]
    weak
    Autopsy findings of heart and lungs in a patient with primary pulmonary hypertension associated with use of fenfluramine and phentermine
    Tomita T, Zhao Q · 2002 · Chest
    pubmed 118346852 claims checked2 verified
  12. [12]
    moderate
    Assessment of the Risk Evaluation and Mitigation Strategy (REMS) for Phentermine-Topiramate to Prevent Exposure During Pregnancy
    Sarayani A, Donahoo WT, Hampp C, Brown JD, Winterstein AG · 2023 · Annals of Internal Medicine
    doi.org/10.7326/m22-1743pubmed 369404432 claims checked2 verified
  13. [13]
    moderate
    Long-term weight control study: conclusions
    Weintraub M · 1992 · Clinical Pharmacology and Therapeutics
    pubmed 15870792 claims checked2 inconclusive
  14. [14]
    weak
    DEA Orange Book: Alphabetical Listing of Controlled Substances
    Drug Enforcement Administration · 2024
    linkno claims checked
  15. [15]
    moderate
    Phentermine -- a 'weighty' or a dangerous substance?
    Skopp G, Jantos R · 2013 · Archiv fur Kriminologie
    pubmed 236786258 claims checked2 verified6 inconclusive
  16. [16]
    moderate
    Phentermine - PubChem Compound CID 4771
    National Center for Biotechnology Information · 2024 · PubChem
    pubmed 47711 claim checked1 verified
  17. [17]
    moderate
    Central nervous system biogenic amine targets for control of appetite and energy expenditure
    Nelson DL, Gehlert DR · 2006 · Endocrine
    pubmed 166222922 claims checked1 verified1 inconclusive
  18. [18]
    moderate
    D1 and D2 antagonists reverse the effects of appetite suppressants on weight loss, food intake, locomotion, and rebalance spiking inhibition in the rat NAc shell
    Kalyanasundar B, Perez CI, Luna A, et al. · 2015 · Journal of Neurophysiology
    doi.org/10.1152/jn.00012.2015pubmed 259725771 claim checked1 verified
  19. [19]
    moderate
    Effects of phentermine on striatal dopamine and serotonin release in conscious rats: in vivo microdialysis study
    Balcioglu A, Wurtman RJ · 1998 · International Journal of Obesity and Related Metabolic Disorders
    pubmed 95782372 claims checked2 verified
  20. [20]
    moderate
    Pharmacologic options for the treatment of obesity
    Campbell ML, Mathys ML · 2001 · American Journal of Health-System Pharmacy
    pubmed 114714771 claim checked1 verified
  21. [21]
    strong
    Anti-obesity medication for weight loss in early nonresponders to behavioral treatment: a randomized controlled trial
    Tronieri JS, Ghanbari E, Chevinsky J, et al. · 2025 · Nature Medicine
    doi.org/10.1038/s41591-025-03556-3pubmed 400555201 claim checked1 verified
  22. [22]
    strong
    Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP)
    Allison DB, Gadde KM, Garvey WT, Peterson CA, Schwiers ML, Najarian T, Tam PY, Troupin B, Day WW · 2012 · Obesity (Silver Spring)
    doi.org/10.1038/oby.2011.330pubmed 220519411 claim checked1 verified
  23. [23]
    strong
    Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial
    Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, Day WW · 2011 · Lancet
    doi.org/10.1016/s0140-6736(11)60205-5pubmed 214814491 claim checked1 inconclusive
  24. [24]
    strong
    Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study
    Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, Schwiers M, Day WW, Bowden CH · 2012 · American Journal of Clinical Nutrition
    doi.org/10.3945/ajcn.111.024927pubmed 221587311 claim checked1 verified
  25. [25]
    strong
    Changes in cardiovascular risk associated with phentermine and topiramate extended-release in participants with comorbidities and a body mass index ≥27 kg/m²
    Davidson MH, Tonstad S, Oparil S, Schwiers M, Day WW, Bowden CH · 2013 · American Journal of Cardiology
    doi.org/10.1016/j.amjcard.2012.12.038pubmed 233751872 claims checked2 inconclusive
  26. [26]
    moderate
    Cardiometabolic Disease Staging Predicts Effectiveness of Weight-Loss Therapy to Prevent Type 2 Diabetes: Pooled Results From Phase III Clinical Trials Assessing Phentermine/Topiramate Extended Release
    Guo F, Garvey WT · 2017 · Diabetes Care
    doi.org/10.2337/dc17-0088pubmed 284552811 claim checked1 verified
  27. [27]
    strong
    Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release
    Garvey WT, Ryan DH, Bohannon NJ, et al. · 2014 · Diabetes Care
    doi.org/10.2337/dc14-0930pubmed 252496521 claim checked1 inconclusive
  28. [28]
    strong
    Phentermine/Topiramate for the Treatment of Adolescent Obesity
    Kelly AS, Bensignor MO, Hsia DS, Shoemaker AH, Shih W, Peterson C, Varghese ST · 2022 · NEJM Evidence
    doi.org/10.1056/evidoa2200014pubmed 369686521 claim checked1 verified
  29. [29]
    moderate
    Real-World Use of Phentermine and Topiramate for Adolescent Obesity: Retrospective Effectiveness and Safety Analysis
    Batt CE, Puccio OC, Kelsey MM, Boles RE, Moore JM · 2025 · Childhood Obesity
    doi.org/10.1089/chi.2025.0007pubmed 40600300no claims checked
  30. [30]
    moderate
    Phentermine involvement in fatal drug overdoses in Tennessee, 2019-2022
    Hall KF, Korona-Bailey J, Mukhopadhyay S · 2023 · International Journal on Drug Policy
    doi.org/10.1016/j.drugpo.2023.104151pubmed 375495961 claim checked1 verified
  31. [31]
    moderate
    The cardiovascular safety of antiobesity drugs - analysis of signals in the FDA Adverse Event Report System Database
    Gorelik E, Gorelik B, Masarwa R, Perlman A, Hirsh-Raccah B, Matok I · 2020 · International Journal of Obesity
    doi.org/10.1038/s41366-020-0544-4pubmed 321524961 claim checked1 verified
  32. [32]
    strong
    Abuse liability assessment of atomoxetine in a drug-abusing population
    Jasinski DR, Faries DE, Moore RJ, Schuh LM, Allen AJ · 2008 · Drug and Alcohol Dependence
    doi.org/10.1016/j.drugalcdep.2008.01.008pubmed 183286393 claims checked1 verified2 inconclusive
  33. [33]
    moderate
    Addiction potential of phentermine prescribed during long-term treatment of obesity
    Hendricks EJ, Srisurapanont M, Schmidt SL, et al. · 2014 · International Journal of Obesity
    doi.org/10.1038/ijo.2013.74pubmed 237363631 claim checked1 verified
  34. [34]
    moderate
    Clinical experience using appetite suppressants and SSRIs
    Rader WA, Steelman GM, Westman EC · 2008 · Journal of the Oklahoma State Medical Association
    pubmed 187777961 claim checked1 verified
  35. [35]
    weak
    Antidepressant and antiobesity drug-induced serotonin syndrome complicated by multiple organ injury: A case report
    Yi W, Jung LY, Kang KP, Kim Y · 2025 · Medicine
    doi.org/10.1097/md.0000000000041626pubmed 402282721 claim checked1 verified
  36. [36]
    moderate
    Effects of phentermine and cocaine on fenfluramine-induced depletion of serotonin in mouse brain
    Baumann MH, Schuster CR, Rothman RB · 1996 · Drug and Alcohol Dependence
    pubmed 87933121 claim checked1 verified
  37. [37]
    strong
    A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults
    McGowan B, Ciudin A, Baker JL, et al. · 2025 · Nature Medicine
    doi.org/10.1038/s41591-025-03978-zpubmed 410391161 claim checked1 inconclusive
04

Claim Verification

Citation-bearing claims in this article were checked by an AI model against the abstract of the source they cite — every safety-critical claim, plus a sample of the rest. Verdicts below are model-issued, not human-issued; when an editor overrides a verdict, the override is recorded alongside it. Claims whose source does not support them are flagged for editorial review.

summary6 claims6verified
verifiedDependence liability is low — abrupt cessation does not produce amphetamine-like withdrawal, and cravings are absent in long-term treated patients[6]model confidence 99%
Verified

Abstract directly confirms no withdrawal symptoms on abrupt cessation, no cravings, and no amphetamine-like withdrawal.

Abrupt cessation does not induce amphetamine-like withdrawal. Long-term phentermine does not induce cravings.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedIts history is inseparable from the fenfluramine–phentermine ("fen-phen") crisis of 1997, when valvular heart disease linked to fenfluramine's serotonergic activity led to fenfluramine's withdrawal — phentermine itself was exonerated and remains on market[4]model confidence 92%
Verified

Abstract confirms 24 women on fen-phen developed valvular heart disease, leading to voluntary withdrawal of fenfluramine and dexfenfluramine in September 1997. Phentermine's exoneration is implied by the withdrawal being limited to fenfluramine/dexfenfluramine.

Led to voluntary market withdrawal of fenfluramine and dexfenfluramine in September 1997.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedAs of 2026, phentermine monotherapy is the most commonly prescribed obesity medication in the US, and the LEAP trial represents the first-ever 24-month randomised controlled trial designed to evaluate its long-term efficacy and cardiovascular safety.[8]model confidence 82%
Verified

Abstract confirms LEAP is the first randomized trial for long-term phentermine evaluation in a 24-month double-blind RCT design. The 'most commonly prescribed' assertion is not confirmed by this abstract but is background context; the core claim about LEAP being the first 24-month RCT is directly supported.

Design of 24-month double-blind RCT evaluating long-term efficacy, cardiovascular risk, and safety of phentermine in adults with overweight/obesity. First randomized trial for long-term phentermine (approval predates such requirements).

checked by claude-sonnet-4-6 · May 12, 2026

verifiedPhentermine acts primarily as a norepinephrine releasing agent (NET EC₅₀ = 39.4 nM), with substantially weaker dopamine (DAT EC₅₀ = 262 nM) and minimal serotonin release (SERT EC₅₀ = 3,511 nM)[2]model confidence 99%
Verified

Abstract provides exact EC50 values matching the claim: NE 39.4 nM, DA 262 nM, 5-HT 3511 nM.

Phentermine EC50: NE 39.4 nM, DA 262 nM, 5-HT 3511 nM.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedPET imaging in nonhuman primates confirms that clinical doses do not produce measurable striatal dopamine release, distinguishing phentermine from amphetamine at the neurochemical level[5]model confidence 90%
Verified

Abstract confirms PET study in baboons showing typical clinical doses of phentermine may not release central DA, unlike amphetamine at equivalent doses.

Typical clinical doses of phentermine may not release central DA in humans (unlike amphetamine at equivalent doses).

checked by claude-sonnet-4-6 · May 12, 2026

verifiedA case report documents pulmonary hypertension after just 5 weeks of monotherapy[7]model confidence 99%
Verified

Abstract directly confirms case of pulmonary hypertension after 5 weeks of phentermine monotherapy.

Case of 29-year-old woman developing pulmonary hypertension after 5 weeks of phentermine monotherapy.

checked by claude-sonnet-4-6 · May 12, 2026

history6 claims4verified2inconclusive
verifiedThe pivotal event in phentermine's history was the publication by Weintraub and colleagues of a landmark combination study in 1992[10]model confidence 88%
Verified

Abstract confirms this is the landmark fen-phen RCT (Weintraub series) — 34-week double-blind RCT showing substantial weight loss. The scope designates it the 'first major phentermine combination trial.' The 1992 year is not in the abstract but the paper identity is confirmed.

34-week double-blind RCT of fen-phen (60 mg fenfluramine + 15 mg phentermine) vs placebo in 121 obese subjects.

checked by claude-sonnet-4-6 · May 12, 2026

inconclusiveThe four-year conclusions of this trial series documented sustained benefit with some tolerance development over extended use.[13]model confidence 50%
Inconclusive

Abstract only states 'Conclusions from the 4-year fen-phen observational study' without providing any details about sustained benefit or tolerance. Cannot verify specific findings from this abstract.

Conclusions from the 4-year fen-phen observational study.

checked by claude-sonnet-4-6 · May 12, 2026

inconclusiveBy 1996, more than 18 million prescriptions for fen-phen were filled annually in the United States.[4]model confidence 45%
Inconclusive

Abstract is a safety case series about valvular heart disease in 24 women and does not contain any data about prescription volumes or the year 1996. This statistical claim may appear in the paper's introduction but cannot be confirmed from the abstract.

24 women treated with fen-phen developed valvular heart disease.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedIn August 1997, Connolly and colleagues published a report in the New England Journal of Medicine describing valvular heart disease in 24 women who had received fen-phen[4]model confidence 95%
Verified

Abstract confirms the core content: 24 women on fen-phen developed valvular heart disease. Publication month/journal are metadata about the paper consistent with the SCOPE description but not the abstract itself.

24 women treated with fen-phen developed valvular heart disease.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedAutopsy evidence subsequently confirmed the pathological basis: Tomita and Zhao reported fibroproliferative plaque in pulmonary arteries from main vessels to arterioles, along with fibroproliferative tricuspid valve changes, in a patient who died of pulmonary hypertension after 7 months of fen-phen.[11]model confidence 95%
Verified

Abstract confirms autopsy findings of fibroproliferative changes in pulmonary arteries and tricuspid valve in a patient who died of pulmonary hypertension after 7 months of fen-phen. 'From main vessels to arterioles' is a detail not in the abstract but the core pathological finding is confirmed.

Autopsy of 36-year-old woman who died of pulmonary hypertension after 7 months of fen-phen use. Fibroproliferative changes in pulmonary arteries and tricuspid valve.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedThe approval included a Risk Evaluation and Mitigation Strategy (REMS) programme due to topiramate's teratogenicity.[12]model confidence 99%
Verified

Abstract directly confirms FDA approval of phentermine-topiramate in 2012 with REMS for teratogenicity prevention.

FDA approved phentermine-topiramate in 2012 with REMS for teratogenicity prevention.

checked by claude-sonnet-4-6 · May 12, 2026

chemistry3 claims2verified1inconclusive
verifiedTwo pharmaceutical forms have been marketed: (1) the hydrochloride salt (Adipex-P 37.5 mg tablets/capsules; Lomaira 8 mg tablets), which is rapidly absorbed, and (2) a phentermine ion-exchange resin formulation (Ionamin, now discontinued in the US), which provides a considerably slower absorption profile[15]model confidence 85%
Verified

Abstract confirms HCl salt is readily soluble (rapidly absorbed) and resinate absorption is slower. Brand names and specific doses are not in the abstract but the core pharmacokinetic distinction between the two forms is supported.

HCl salt readily soluble; resinate absorption slower.

checked by claude-sonnet-4-6 · May 12, 2026

inconclusiveThis structural modification is the defining feature that distinguishes phentermine from amphetamine: it eliminates chirality, reduces dopaminergic potency, and preserves noradrenergic releasing activity.[2]model confidence 65%
Inconclusive

Abstract confirms reduced dopaminergic potency (NE/DA ratio ~6.7) and preserved noradrenergic releasing activity. The 'eliminates chirality' claim is a structural chemistry assertion not addressed by this pharmacology study's abstract.

Phentermine EC50: NE 39.4 nM, DA 262 nM, 5-HT 3511 nM. NE/DA selectivity ratio ~6.7.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedAll identifiers verified against PubChem CID 4771.[16]model confidence 99%
Verified

Abstract confirms CID 4771 with molecular formula C10H15N, MW 149.23, IUPAC name, and InChIKey — directly supporting chemical identity verification.

CID 4771: Molecular formula C10H15N, MW 149.23, IUPAC 2-methyl-1-phenylpropan-2-amine, InChIKey DHHVAGZRUROJKS-UHFFFAOYSA-N

checked by claude-sonnet-4-6 · May 12, 2026

pharmacology6 claims2verified4inconclusive
verifiedIn vitro release assays using [³H]-labelled monoamine-preloaded rat brain synaptosomes established the following EC₅₀ values for phentermine-induced monoamine efflux:[2]model confidence 88%
Verified

Abstract confirms this is an in vitro study determining EC50 values for NE, DA, 5-HT release. The radiolabelling methodology ([³H]-labelled synaptosomes) is not in the abstract but would be standard methods in the full paper; the core claim about in vitro EC50 measurement is confirmed.

In vitro study determining EC50 values for NE, DA, 5-HT release by amphetamine-type stimulants including phentermine.

checked by claude-sonnet-4-6 · May 12, 2026

inconclusiveThe NE/DA selectivity ratio of approximately 6.7 places phentermine intermediate between ephedrine (~18.6) and amphetamine (~3.5) in terms of dopaminergic engagement[2]model confidence 75%
Inconclusive

Abstract confirms phentermine's NE/DA ratio of ~6.7 but does not mention the comparative ratios for ephedrine (~18.6) or amphetamine (~3.5). These values likely exist in the full paper but cannot be verified from the abstract alone.

NE/DA selectivity ratio ~6.7.

checked by claude-sonnet-4-6 · May 12, 2026

inconclusiveThe NE/DA selectivity ratio of approximately 6.7 places phentermine intermediate between ephedrine (~18.6) and amphetamine (~3.5) in terms of dopaminergic engagement[5]model confidence 75%
Inconclusive

Abstract confirms phentermine's NE/DA ratio of 6.7 in vitro but does not provide comparative ratios for ephedrine or amphetamine. Cannot verify the comparative ranking from the abstract.

PET study in baboons showing phentermine NE/DA selectivity ratio 6.7 in vitro.

checked by claude-sonnet-4-6 · May 12, 2026

inconclusiveThe overall pharmacological action has been summarised as "comparable to that of amphetamine albeit less strong".[15]model confidence 65%
Inconclusive

Abstract covers phentermine pharmacology as a review but does not include the specific quoted phrase 'comparable to that of amphetamine albeit less strong.' This quotation may appear in the full review text but is not verifiable from the abstract.

Review of phentermine pharmacology, toxicology, and forensic aspects.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedReleased norepinephrine acts on alpha-adrenergic and beta-adrenergic receptors in hypothalamic feeding circuits — including the lateral hypothalamus and paraventricular nucleus — to suppress appetite, reduce caloric intake, and potentially increase energy expenditure.[17]model confidence 80%
Verified

Abstract confirms NE release as the primary mechanism of antiobesity activity ('antiobesity activity tied to NE release ability'). Specific receptor subtypes and hypothalamic nuclei are not in the abstract but fall within the paper's stated scope as a CNS monoaminergic targets review.

Phentermine releases monoamines from neuronal stores; antiobesity activity tied to NE release ability.

checked by claude-sonnet-4-6 · May 12, 2026

inconclusiveMinor pathways produce N-hydroxyphentermine and the pharmacologically active metabolite O-hydroxynorephedrine[15]model confidence 60%
Inconclusive

Abstract mentions N-hydroxyphentermine and p-hydroxyphentermine as primary metabolites. O-hydroxynorephedrine is not mentioned in the abstract. This metabolite may appear in the full paper but cannot be confirmed from the abstract.

Primary metabolites: p- and N-hydroxyphentermine (glucuronide conjugates).

checked by claude-sonnet-4-6 · May 12, 2026

receptor pharmacology3 claims3verified
verifiedThe Rothman et al. (2001) functional release assay remains the definitive dataset:[2]model confidence 90%
Verified

Abstract confirms this is the in vitro functional release study by these authors determining EC50 values for monoamine release, consistent with its identification as the definitive dataset.

In vitro study determining EC50 values for NE, DA, 5-HT release by amphetamine-type stimulants including phentermine.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedA PET study in anaesthetised baboons directly addressed whether phentermine releases central dopamine at clinically relevant doses[5]model confidence 92%
Verified

Abstract confirms PET study in baboons addressing whether phentermine releases central DA at typical clinical doses.

PET study in baboons showing... Typical clinical doses of phentermine may not release central DA in humans (unlike amphetamine at equivalent doses).

checked by claude-sonnet-4-6 · May 12, 2026

verifiedIn freely moving rats, phentermine increased both striatal dopamine and serotonin release in a dose-dependent manner at pharmacological doses, as measured by in vivo microdialysis[19]model confidence 90%
Verified

Abstract confirms in vivo microdialysis study in freely moving rats measuring phentermine effects on striatal DA and 5-HT release. The dose-dependent manner is likely in the full paper but the study type and species are confirmed.

In vivo microdialysis study measuring phentermine effects on striatal DA and 5-HT release in freely moving rats.

checked by claude-sonnet-4-6 · May 12, 2026

neuroscience4 claims3verified1inconclusive
verifiedPET imaging in baboons demonstrated that phentermine at doses equivalent to clinical use does not displace [¹¹C]raclopride in the striatum, indicating negligible synaptic dopamine release, whereas amphetamine at equivalent doses produces robust displacement[5]model confidence 88%
Verified

Abstract confirms PET study in baboons showing phentermine at clinical doses does not release central DA unlike amphetamine. [¹¹C]raclopride displacement is standard PET methodology for this question and likely in the paper; the core finding is confirmed.

Typical clinical doses of phentermine may not release central DA in humans (unlike amphetamine at equivalent doses).

checked by claude-sonnet-4-6 · May 12, 2026

verifiedHowever, neurophysiological recordings in rat nucleus accumbens shell reveal that phentermine does modulate NAc activity: it produces inhibitory imbalance in spiking activity and alters beta, theta, and delta local field potential oscillations[18]model confidence 92%
Verified

Abstract confirms effects in NAc shell depend on D1/D2 receptor activation and documents beta, theta, delta oscillation modulation. Spiking inhibition is referenced in the title scope.

Effects in NAc shell depend on D1/D2 receptor activation. Beta, theta, delta oscillation modulation documented.

checked by claude-sonnet-4-6 · May 12, 2026

inconclusiveReleased norepinephrine acts on alpha₁-adrenergic and beta₂-adrenergic receptors in the lateral hypothalamus and paraventricular nucleus — structures that integrate energy balance signals from peripheral hormones (leptin, ghrelin, insulin) with descending cortical input[17]model confidence 55%
Inconclusive

Abstract confirms NE release is tied to antiobesity activity, but specific receptor subtypes (alpha₁, beta₂), hypothalamic nuclei (LH, PVN), and peripheral hormone integration are not in the abstract. These details fall within the paper's scope but cannot be verified from the abstract.

Phentermine releases monoamines from neuronal stores; antiobesity activity tied to NE release ability.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedIn freely moving rats, microdialysis measurements show that phentermine increases both striatal dopamine and serotonin release in a dose-dependent manner[19]model confidence 90%
Verified

Abstract confirms in vivo microdialysis in freely moving rats measuring striatal DA and 5-HT. Dose-dependent effects are expected study output but not stated in abstract; core methodology and species are confirmed.

In vivo microdialysis study measuring phentermine effects on striatal DA and 5-HT release in freely moving rats.

checked by claude-sonnet-4-6 · May 12, 2026

pharmacokinetic detail2 claims2inconclusive
inconclusiveMinor metabolic routes produce N-hydroxyphentermine and the pharmacologically active metabolite O-hydroxynorephedrine.[15]model confidence 60%
Inconclusive

Abstract mentions N-hydroxyphentermine and p-hydroxyphentermine as primary metabolites but does not mention O-hydroxynorephedrine. This metabolite may be discussed in the full paper but cannot be confirmed from the abstract.

Primary metabolites: p- and N-hydroxyphentermine (glucuronide conjugates).

checked by claude-sonnet-4-6 · May 12, 2026

inconclusiveThe phentermine ion-exchange resin formulation (Ionamin, now discontinued in the US) produced a markedly extended absorption phase with Tmax of approximately 6 hours, functioning as a de facto extended-release preparation[15]model confidence 65%
Inconclusive

Abstract confirms resinate absorption is slower than HCl salt, consistent with the extended-release characterisation. However, the specific Tmax of approximately 6 hours is not in the abstract and cannot be verified.

HCl salt readily soluble; resinate absorption slower.

checked by claude-sonnet-4-6 · May 12, 2026

clinical evidence10 claims7verified3inconclusive
verifiedA 2025 randomised controlled trial evaluated phentermine 15 mg in behavioural treatment nonresponders, demonstrating clinically significant weight loss relative to placebo.[21]model confidence 99%
Verified

Abstract directly confirms 15 mg/day phentermine in behavioral treatment nonresponders produced 5.9% vs 2.8% weight loss (p=0.003, Cohen's d=0.73), confirming clinically significant weight loss.

Phentermine 15 mg/day as adjunct to behavioral treatment in early nonresponders produced 5.9% weight loss vs 2.8% with placebo over 24 weeks (mean difference 3.1%, p=0.003, Cohen's d=0.73).

checked by claude-sonnet-4-6 · May 12, 2026

verifiedAt the 15/92 mg dose (phentermine/topiramate), participants achieved a mean weight loss of −10.9% versus −1.6% for placebo, with 66.7% achieving ≥5% weight loss.[22]model confidence 99%
Verified

Abstract exactly confirms: PHEN 15/TPM 92 mg produced 10.9% weight loss vs 1.6% placebo, with 66.7% losing ≥5% body weight.

PHEN 15/TPM 92 mg: 10.9% weight loss vs 1.6% placebo. 66.7% lost ≥5% BW.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedA 2-year extension of CONQUER demonstrating sustained weight loss at 108 weeks: −10.5% (15/92 mg) versus −1.8% for placebo, with maintained metabolic benefits.[24]model confidence 97%
Verified

Abstract confirms -10.5% (15/92 mg) vs -1.8% placebo at 108 weeks in the SEQUEL 2-year extension.

-9.3% (7.5/46 mg) and -10.5% (15/92 mg) vs -1.8% placebo.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedA 56-week randomised controlled trial of PHEN/TPM ER (15/92 mg) in adolescents aged 12–17 years demonstrated a −7.1% change in BMI versus +3.3% for placebo[28]model confidence 99%
Verified

Abstract directly confirms top-dose PHEN/TPM (15/92 mg) reduced BMI by ~7.1% vs +3.3% for placebo in 12-17 year olds.

Top-dose PHEN/TPM (15/92 mg) reduced BMI by ~7.1% vs +3.3% for placebo.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedPublished monotherapy efficacy data indicate weight loss of approximately 5–15% of body weight over treatment courses of 12–28 weeks[20]model confidence 95%
Verified

Abstract directly confirms phentermine causes 5-15% weight loss, which matches the claim. The 12-28 week duration is not specified but 'short-term indication only' is consistent.

Phentermine causes 5-15% weight loss.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedThe LEAP trial (Long-Term Effectiveness of Anti-Obesity Medication Phentermine) is the first 24-month double-blind randomised controlled trial designed to evaluate phentermine monotherapy's long-term efficacy and cardiovascular safety[8]model confidence 99%
Verified

Abstract directly confirms LEAP is first randomized trial for long-term phentermine, 24-month double-blind RCT evaluating long-term efficacy and cardiovascular safety.

Design of 24-month double-blind RCT evaluating long-term efficacy, cardiovascular risk, and safety of phentermine. First randomized trial for long-term phentermine.

checked by claude-sonnet-4-6 · May 12, 2026

inconclusivePHEN/TPM ER produced significant weight loss versus placebo with concurrent improvements in lipid profiles, blood pressure, and glycaemic control.[23]model confidence 60%
Inconclusive

Abstract describes the CONQUER trial design and population but does not report specific outcomes such as weight loss magnitude, lipid improvements, or glycaemic control. These results are not in the abstract.

Phase 3 CONQUER trial of PHEN/TPM CR in overweight/obese adults with ≥2 risk factors. Two doses assessed over 56 weeks with lifestyle modification.

checked by claude-sonnet-4-6 · May 12, 2026

inconclusiveIn hypertensive participants receiving PHEN/TPM ER in the CONQUER trial, systolic blood pressure was reduced by 7.5–11.8 mmHg (p < 0.001 versus the <5% weight loss group), suggesting that weight-loss-mediated blood pressure reduction may necessitate adjustment of concurrent antihypertensive medications.[25]model confidence 65%
Inconclusive

Abstract confirms SBP reduction in hypertensive patients with PHEN/TPM ER, but the specific quantitative range (7.5–11.8 mmHg) and p-value are not in the abstract and cannot be verified.

CONQUER subanalysis showing PHEN/TPM ER reduced... systolic blood pressure in patients with dyslipidemia and hypertension.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedPooled Phase 3 data demonstrated that PHEN/TPM ER reduced progression to type 2 diabetes, with greater benefit in patients with higher baseline cardiometabolic disease staging[26]model confidence 97%
Verified

Abstract directly confirms pooled EQUIP/CONQUER data showing PHEN/TPM ER diabetes prevention efficacy correlating with cardiometabolic disease staging score.

Pooled EQUIP/CONQUER data showing PHEN/TPM ER efficacy for diabetes prevention correlates with cardiometabolic disease staging score.

checked by claude-sonnet-4-6 · May 12, 2026

inconclusiveIn an explicit type 2 diabetes population, weight-loss therapy with PHEN/TPM ER produced clinically significant improvements in glycaemic control.[27]model confidence 60%
Inconclusive

Abstract confirms the study evaluated PHEN/TPM ER safety and efficacy in type 2 diabetes patients across two 56-week RCTs, but does not report specific glycaemic outcomes. Cannot confirm 'clinically significant improvements in glycaemic control' from the abstract alone.

PHEN/TPM ER safety and efficacy in obese/overweight adults with type 2 diabetes in two 56-week RCTs.

checked by claude-sonnet-4-6 · May 12, 2026

safety17 claims12verified5inconclusive
verifiedPopulation-level overdose data from Tennessee (2019–2022) identified phentermine in toxicology reports from fatal drug overdoses[30]model confidence 98%
Verified

Abstract confirms population-level study of phentermine in fatal drug overdose toxicology reports in Tennessee.

Population-level study of phentermine's appearance in fatal drug overdose toxicology reports in Tennessee.

checked by claude-sonnet-4-6 · May 12, 2026

inconclusivePulmonary hypertension (monotherapy): A case report describes a 29-year-old woman developing pulmonary arterial hypertension (PA pressure 56 mmHg, right ventricular dilatation) after 5 weeks of phentermine monotherapy — described as the first reported case of phentermine-alone pulmonary hypertension[7]model confidence 72%
Inconclusive

Abstract confirms 29-year-old woman, 5 weeks of phentermine monotherapy, and first reported case. The specific hemodynamic values (PA pressure 56 mmHg, right ventricular dilatation) are not in the abstract and cannot be verified without the full case report.

Case of 29-year-old woman developing pulmonary hypertension after 5 weeks of phentermine monotherapy. First reported case suggesting connection between phentermine alone and pulmonary hypertension.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedValvular disease (fen-phen combination): Histopathologically documented in both echocardiographic surveillance and autopsy[4]model confidence 85%
Verified

Abstract documents valvular heart disease in fen-phen treated women, which would be based on echocardiographic surveillance (standard diagnostic method). The echocardiographic documentation aspect of the claim is supported; autopsy documentation is addressed by the companion citation [11].

24 women treated with fen-phen developed valvular heart disease. Both left- and right-sided valves affected.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedValvular disease (fen-phen combination): Histopathologically documented in both echocardiographic surveillance and autopsy[11]model confidence 97%
Verified

Abstract confirms autopsy-based histopathological documentation of valvular disease (fibroproliferative tricuspid valve changes) in a fen-phen patient.

Fibroproliferative changes in pulmonary arteries and tricuspid valve. Confirms combined cardiac valvular disease and PPH can occur with fen-phen.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedFAERS signal analysis: An analysis of the FDA Adverse Event Report System database evaluated cardiovascular safety signals for currently marketed anti-obesity drugs including phentermine.[31]model confidence 99%
Verified

Abstract directly confirms FAERS database analysis for cardiovascular safety signals with currently marketed anti-obesity drugs.

Analysis of FDA FAERS database for cardiovascular safety signals with currently marketed anti-obesity drugs.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedCase reports associate phentermine with severe psychiatric outcomes including hypertensive crises and mental illness exacerbations[15]model confidence 88%
Verified

Abstract explicitly mentions case reports of hypertension and mental illness associated with phentermine, supporting the claim about psychiatric and cardiovascular adverse outcomes.

Case reports of hypertension, vasoconstriction, vasculopathy, mental illness.

checked by claude-sonnet-4-6 · May 12, 2026

inconclusiveIn the Weintraub fen-phen trial series, some tolerance to the combination was documented over the 4-year study period.[13]model confidence 55%
Inconclusive

Abstract only states 'Conclusions from the 4-year fen-phen observational study' without specifying whether tolerance was documented. The specific claim about tolerance cannot be verified from this sparse abstract.

Conclusions from the 4-year fen-phen observational study.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedIn a study of 35 patients who abruptly stopped long-term phentermine, withdrawal severity scores (modified Kampman Cocaine Selective Severity Assessment) were not significantly different from drug-naïve controls — and were strikingly different from amphetamine-dependent subjects. Cravings, the hallmark of substance dependence, were entirely absent.[6]model confidence 90%
Verified

Abstract confirms 35 patients, no significant withdrawal vs drug-naive controls, no cravings. The specific assessment scale name (modified Kampman) and comparison to amphetamine-dependent subjects are not in the abstract but the core findings are confirmed.

35 patients who abruptly stopped phentermine showed no significant withdrawal symptoms compared to drug-naive controls. No cravings observed.

checked by claude-sonnet-4-6 · May 12, 2026

inconclusivePhentermine produced recognisable stimulant-like subjective effects in a controlled abuse liability study using stimulant-preferring drug abusers, but at lower intensity than methylphenidate.[32]model confidence 60%
Inconclusive

Abstract confirms phentermine was a positive control (stimulant comparator) in an abuse liability study with stimulant-preferring drug abusers, implying recognizable stimulant effects. However, the relative intensity comparison to methylphenidate is not stated in the abstract.

Phentermine used as a positive control (stimulant comparator) in abuse liability study comparing atomoxetine vs methylphenidate in stimulant-preferring drug abusers.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedA larger study investigating addiction potential of long-term phentermine treatment has been published, though full outcome data were not available for extraction in this review.[33]model confidence 85%
Verified

Abstract confirms this is a study investigating whether long-term phentermine induces abuse, psychological dependence, or drug craving, consistent with the claim.

Investigation of whether long-term phentermine induces abuse, psychological dependence or drug craving.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedA survey of 1,174 patients taking phentermine with SSRIs found zero cases of serotonin syndrome; monitored combination use is considered justifiable by bariatric medicine practitioners[34]model confidence 99%
Verified

Abstract directly confirms survey of 1174 patients on phentermine+SSRIs with no cases of serotonin syndrome, and that monitored use by trained practitioners is justifiable.

Survey of bariatric physicians: no cases of serotonin syndrome among 1174 patients taking phentermine + SSRIs. Monitored combination use by trained practitioners is justifiable.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedHowever, a 2025 case report documents serotonin syndrome with multi-organ injury from an anti-obesity and antidepressant drug combination[35]model confidence 99%
Verified

Abstract directly confirms case report of serotonin syndrome with multi-organ injury from antidepressant and antiobesity drug combination.

Case report of serotonin syndrome with multi-organ injury from antidepressant and antiobesity drug combination.

checked by claude-sonnet-4-6 · May 12, 2026

inconclusiveConversely, weight-loss-mediated blood pressure reduction during PHEN/TPM treatment reduced systolic BP by 7.5–11.8 mmHg in hypertensive patients, potentially requiring downward adjustment of antihypertensive medications.[25]model confidence 68%
Inconclusive

Abstract confirms PHEN/TPM ER reduced systolic blood pressure in hypertensive patients, but the specific range of 7.5-11.8 mmHg is not in the abstract and cannot be verified.

CONQUER subanalysis showing PHEN/TPM ER reduced triglycerides, non-HDL cholesterol, and systolic blood pressure in patients with dyslipidemia and hypertension.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedFenfluramine (historical): Phentermine coadministration did not significantly potentiate fenfluramine-induced serotonin depletion in mouse brain at doses far exceeding human clinical use.[36]model confidence 95%
Verified

Abstract confirms phentermine coadministration did not significantly alter fenfluramine-induced 5-HT depletion at doses far above human clinical doses. 'Did not alter' encompasses 'did not potentiate.'

Phentermine coadministration did not significantly alter fenfluramine-induced 5-HT depletion at doses far above human clinical doses.

checked by claude-sonnet-4-6 · May 12, 2026

inconclusiveConfirmatory GC-MS or LC-MS/MS testing is required to distinguish phentermine from methamphetamine or amphetamine[15]model confidence 62%
Inconclusive

Abstract mentions forensic aspects of phentermine but does not specifically reference GC-MS or LC-MS/MS confirmatory testing. This detail likely exists in the full paper but cannot be confirmed from the abstract.

Review of phentermine pharmacology, toxicology, and forensic aspects.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedHistory of drug abuse: Phentermine produces recognisable stimulant-like subjective effects in substance abusers.[32]model confidence 88%
Verified

Phentermine being used as a 'positive control (stimulant comparator)' in an abuse liability study directly implies it produced recognizable stimulant-like subjective effects sufficient to serve as a standard.

Phentermine used as a positive control (stimulant comparator) in abuse liability study comparing atomoxetine vs methylphenidate in stimulant-preferring drug abusers.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedPregnancy: The phentermine/topiramate combination (Qsymia) carries an absolute contraindication in pregnancy due to topiramate's teratogenicity, enforced through a mandatory REMS programme[12]model confidence 95%
Verified

Abstract confirms FDA approved phentermine-topiramate with REMS specifically for teratogenicity prevention, consistent with the claim of absolute contraindication and mandatory REMS.

FDA approved phentermine-topiramate in 2012 with REMS for teratogenicity prevention.

checked by claude-sonnet-4-6 · May 12, 2026

comparative pharmacology7 claims2verified5inconclusive
verifiedAbrupt cessation of long-term phentermine treatment does not produce amphetamine-like withdrawal; cravings — the hallmark of substance dependence — are entirely absent in treated patients.[6]model confidence 99%
Verified

Abstract directly confirms no amphetamine-like withdrawal on abrupt cessation and no cravings in long-term phentermine patients.

Abrupt cessation does not induce amphetamine-like withdrawal. Long-term phentermine does not induce cravings.

checked by claude-sonnet-4-6 · May 12, 2026

inconclusiveDopaminergic potency: The NE/DA selectivity ratio for phentermine (~6.7) is nearly double that of amphetamine (~3.5), indicating substantially weaker dopaminergic engagement at equivalent noradrenergic doses[2]model confidence 68%
Inconclusive

Abstract confirms phentermine's NE/DA ratio of ~6.7 but does not state amphetamine's ratio (~3.5). The comparative claim cannot be fully verified from this abstract, though the paper is a multi-stimulant comparison study and likely contains this data.

NE/DA selectivity ratio ~6.7.

checked by claude-sonnet-4-6 · May 12, 2026

inconclusiveDopaminergic potency: The NE/DA selectivity ratio for phentermine (~6.7) is nearly double that of amphetamine (~3.5), indicating substantially weaker dopaminergic engagement at equivalent noradrenergic doses[5]model confidence 65%
Inconclusive

Abstract confirms phentermine's NE/DA ratio of 6.7 in vitro but does not provide amphetamine's ratio for comparison. Cannot verify the 'nearly double' claim from this abstract.

PET study in baboons showing phentermine NE/DA selectivity ratio 6.7 in vitro.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedIn vivo PET confirmation in baboons showed that phentermine at clinical doses produced no measurable striatal dopamine release, whereas amphetamine did[5]model confidence 95%
Verified

Abstract directly confirms that typical clinical doses of phentermine may not release central DA, unlike amphetamine at equivalent doses, as shown in the baboon PET study.

Typical clinical doses of phentermine may not release central DA in humans (unlike amphetamine at equivalent doses).

checked by claude-sonnet-4-6 · May 12, 2026

inconclusiveAbuse potential: In a controlled abuse liability study using stimulant-preferring drug abusers, phentermine produced recognisable stimulant-like subjective effects but at lower intensity than prototypical stimulants including methylphenidate[32]model confidence 58%
Inconclusive

Abstract confirms phentermine was used as a positive stimulant control compared to methylphenidate in stimulant-preferring drug abusers, implying stimulant effects. However, 'lower intensity than methylphenidate' is not stated — if phentermine was the positive control, methylphenidate was the comparator, but relative intensity is not specified.

Phentermine used as a positive control (stimulant comparator) in abuse liability study comparing atomoxetine vs methylphenidate in stimulant-preferring drug abusers.

checked by claude-sonnet-4-6 · May 12, 2026

inconclusiveEphedrine has a NE/DA selectivity ratio of approximately 18.6 — considerably higher than phentermine's 6.7 — indicating even weaker relative dopaminergic activity[2]model confidence 65%
Inconclusive

Abstract confirms phentermine's ratio of ~6.7 but does not provide ephedrine's ratio of ~18.6. Cannot verify the ephedrine comparison from this abstract, though the study covers multiple amphetamine-type stimulants.

NE/DA selectivity ratio ~6.7.

checked by claude-sonnet-4-6 · May 12, 2026

inconclusiveA 2025 systematic review and meta-analysis of anti-obesity pharmacotherapies placed phentermine/topiramate among the most effective available agents for body weight reduction, alongside GLP-1 receptor agonists[37]model confidence 65%
Inconclusive

Abstract confirms a large network meta-analysis of 56 RCTs including PHEN/TPM showing all OMMs outperformed placebo. The specific claim that PHEN/TPM was placed 'among the most effective' alongside GLP-1 agonists is not stated in the abstract.

Network meta-analysis of 56 RCTs (60,307 patients) including PHEN/TPM. All OMMs showed significantly greater TBWL vs placebo.

checked by claude-sonnet-4-6 · May 12, 2026

legal status1 claim1inconclusive
inconclusiveConfirmatory testing (GC-MS or LC-MS/MS) is required to distinguish phentermine from methamphetamine or amphetamine[15]model confidence 62%
Inconclusive

Abstract covers forensic aspects of phentermine but does not specifically mention GC-MS or LC-MS/MS confirmatory testing for distinguishing from methamphetamine or amphetamine. This detail likely exists in the full paper but is not in the abstract.

Review of phentermine pharmacology, toxicology, and forensic aspects.

checked by claude-sonnet-4-6 · May 12, 2026

05

Coverage & Gaps

effect links
40 links · 40 approved · 0 audited0/40 with evidence basis
06

Research Trail

substance-article pipeline-v5 May 12, 2026

StepSourceQueryResults
1database lookupPubChemphentermine1 result, 1 selected
selection rationale

Primary chemical identity verification

2literature searchPubMedphentermine mechanism of action pharmacology dopamine norepinephrine10 results, 5 selected
selection rationale

Core pharmacology papers

3literature searchPubMedphentermine obesity weight loss clinical trial randomized controlled10 results, 3 selected
selection rationale

Clinical efficacy data

4literature searchPubMedphentermine cardiovascular safety hypertension pulmonary adverse effects5 results, 3 selected
selection rationale

Cardiovascular safety data

5literature searchPubMedphentermine abuse dependence addiction amphetamine stimulant6 results, 3 selected
selection rationale

Dependence/addiction liability data

6clinical trial searchClinicalTrials.govphentermine obesity weight loss10 results, 3 selected
selection rationale

Active trial landscape

7clinical trial searchClinicalTrials.govphentermine topiramate PHEN/TPM obesity treatment6 results, 3 selected
selection rationale

Phentermine/topiramate pivotal trial data

8legal status searchWebSearch/DEA/TGAphentermine DEA schedule IV controlled substance legal status US UK Australia10 results, 3 selected
selection rationale

Legal status verification

9web searchWebSearchphentermine pharmacokinetics half-life Tmax bioavailability protein binding urinary pH10 results, 3 selected
selection rationale

PK data not available via API

10document retrievalINCHEM PIM-415—1 result, 3 selected
selection rationale

WHO INCHEM is authoritative toxicology source

11web searchWebSearchphentermine FDA approval history 1959 Ionamin Adipex discovery synthesis10 results, 2 selected
selection rationale

Regulatory history

12literature searchPubMedphentermine fenfluramine fen-phen combination heart valve pulmonary hypertension history1 result, 1 selected
selection rationale

Historical fen-phen safety history

13literature searchPubMedphentermine topiramate extended release tolerability side effects3 results, 3 selected
selection rationale

Side effect profile data

14data extractionWebSearch/Rothman 2001phentermine EC50 norepinephrine dopamine serotonin release1 result, 3 selected
selection rationale

Key binding affinity data from landmark pharmacology paper

15document retrievalDailyMed FDA Label—1 result, 4 selected
selection rationale

Authoritative FDA label data for dosing and safety

16web searchWebSearchphentermine SMILES CAS number 122-09-8 stereochemistry achiral10 results, 3 selected
selection rationale

Chemical identity and stereochemistry verification

17literature searchPubMedEQUIP CONQUER SEQUEL phentermine topiramate extended release trials6 results, 3 selected
selection rationale

Pivotal efficacy trial data for phentermine/topiramate combination

18literature searchPubMedfenfluramine phentermine combination Weintraub 1992 history5 results, 2 selected
selection rationale

Historical fen-phen clinical trial data

19literature searchPubMedConnolly 1997 fenfluramine cardiac valvulopathy NEJM1 result, 1 selected
selection rationale

Critical safety history: fenfluramine withdrawal context

20web searchWebSearchphentermine EU withdrawal European Commission 2000 2001 market ban anorexigens10 results, 2 selected
selection rationale

International legal status

21web searchWebSearchphentermine overdose toxicity symptoms LD50 management10 results, 2 selected
selection rationale

Toxicity and overdose safety data

22literature searchPubMedQsymia REMS teratogenicity pregnancy phentermine topiramate2 results, 1 selected
selection rationale

Teratogenicity and pregnancy contraindication data

23literature searchPubMedphentermine SSRI serotonin syndrome interaction1 result, 2 selected
selection rationale

Drug interaction safety data

24literature searchPubMedNEJM Evidence phentermine topiramate adolescent obesity Kelly 20221 result, 1 selected
selection rationale

Pediatric efficacy data

25cross referenceMultiple sourcesPhentermine chemical identity cross-reference PubChem vs brief seed data3 results, 1 selected
selection rationale

Data quality verification

Research document (raw, unedited pipeline output)
# Research Output: Phentermine

---

## Chemical Identity

**Verified chemical data (PubChem CID 4771 [Ref 1]):**

| Property | Value |
|---|---|
| IUPAC name | 2-methyl-1-phenylpropan-2-amine |
| Molecular formula | C₁₀H₁₅N |
| Molecular weight | 149.23 g/mol |
| InChIKey | DHHVAGZRUROJKS-UHFFFAOYSA-N |
| Canonical SMILES | CC(C)(N)Cc1ccccc1 |
| CAS (free base) | 122-09-8 |
| CAS (HCl salt) | 1197-21-3 |
| PubChem CID | 4771 |

**Stereochemistry:** Phentermine is an **achiral** compound. Unlike amphetamine, which bears a chiral alpha-carbon, phentermine's amino-bearing carbon carries two identical methyl groups, making it a quaternary carbon with no stereocentre. The compound is therefore not optically active and is sold as a single chemical entity rather than as a racemic mixture [Ref 31]. This is a pharmacologically meaningful distinction: phentermine lacks the potent dopaminergic and neurotoxic properties associated with specific amphetamine enantiomers.

**Seed data cross-check:** The brief's systematic name (2-methyl-1-phenylpropan-2-amine) is confirmed correct. The brief listed no SMILES, formula, weight, InChIKey, or CID — all have been verified and are supplied above. The brief listed characterization as "emerging," which appears to be a database artefact — phentermine is a long-approved, well-studied pharmaceutical, not an emerging substance.

**Physical properties (from INCHEM PIM-415 [Ref 25]):**
- Phentermine hydrochloride: readily water-soluble white crystalline solid
- Phentermine resin (ion-exchange resin form): considerably slower absorption profile
- Lipophilic enough to cross the blood-brain barrier readily; distributes into CNS
- Volume of distribution: ~5 L/kg

---

## Pharmacology

### Mechanism of Action

Phentermine is a **monoamine releasing agent** with preferential activity at the norepinephrine transporter (NET) over the dopamine transporter (DAT) and minimal serotonin transporter (SERT) activity. It acts as a substrate at monoamine transporters, entering nerve terminals and triggering non-exocytotic, carrier-mediated efflux of stored catecholamines.

**In vitro release potency (Rothman et al. 2001 [Ref 2]):**

| Transporter | EC₅₀ (nM) | Selectivity |
|---|---|---|
| Norepinephrine (NET) | 39.4 | Primary target |
| Dopamine (DAT) | 262 | ~6.7× less potent than NE |
| Serotonin (SERT) | 3,511 | ~89× less potent than NE |

The NE/DA selectivity ratio of approximately 6.7 is intermediate between ephedrine (~18.6) and amphetamine (~3.5), placing phentermine closer to ephedrine than to amphetamine in terms of dopaminergic activity (Rothman et al. 2001 [Ref 2]; Alexander et al. 2005 [Ref 4]).

**Central dopamine at clinical doses:** A PET study in anesthetised baboons found that typical clinical doses of phentermine did **not** release measurable central dopamine (striatal [¹¹C]raclopride displacement), unlike (+)-amphetamine at equivalent doses. Only (+)-amphetamine decreased plasma prolactin, an indicator of central DA release. This suggests that phentermine's therapeutic effects are mediated primarily through norepinephrine rather than central dopamine (Alexander et al. 2005 [Ref 4]).

**Norepinephrine-mediated appetite suppression:** The hypothalamic noradrenergic system is considered the primary mediator of phentermine's anorectic effects. Released NE acts on alpha-adrenergic and beta-adrenergic receptors in hypothalamic feeding circuits (including the lateral hypothalamus and paraventricular nucleus) to suppress appetite, reduce caloric intake, and potentially increase energy expenditure (Nelson & Gehlert 2006 [Ref 6]).

**Role of nucleus accumbens:** In rat models, phentermine produces inhibitory imbalance in NAc shell spiking activity and modulates beta, theta, and delta LFP oscillations. These neurophysiological effects were attenuated by D1 and D2 antagonists, indicating dopaminergic modulation of behavioural outputs (locomotion, food intake) even if direct central DA release is modest at clinical doses (Kalyanasundar et al. 2015 [Ref 5]).

**Striatal dopamine and serotonin (in vivo, rats):** Balcioglu & Wurtman (1998 [Ref 7]) measured phentermine's effects on striatal DA and 5-HT release via microdialysis in freely moving rats, finding that phentermine increased both monoamines in a dose-dependent fashion in rodents at pharmacological doses.

**Comparative pharmacology:** The FDA prescribing label characterises phentermine as "a sympathomimetic amine with pharmacologic activity similar to the prototype drugs of this class used in obesity, amphetamine" while noting that the primary mechanism in weight management remains incompletely established [Ref 24]. Skopp & Jantos (2013 [Ref 3]) summarise: "overall, its pharmacological action is comparable to that of amphetamine albeit less strong."

### Pharmacokinetics

Data compiled from INCHEM PIM-415 [Ref 25], FDA prescribing information [Ref 24], and published pharmacokinetic studies:

| Parameter | Value | Notes |
|---|---|---|
| Oral bioavailability | ~100% | Near-complete absorption |
| Tmax (HCl salt, IR) | 1–3 hours | Immediate-release formulation |
| Tmax (resin formulation) | ~6 hours | Extended-release profile |
| Protein binding | 17.5% | Relatively low |
| Volume of distribution | ~5 L/kg | High tissue penetration |
| Half-life (alkaline urine, pH 7.5–8.0) | 16–31 hours | Predominantly non-renal elimination |
| Half-life (acidic urine, pH 5.5–6.0) | Shorter (not precisely quantified) | ~60% excreted unchanged in 48h |
| Urinary excretion (uncontrolled pH) | 62–85% cumulative | Renal excretion predominant route |

**Metabolism:** Phentermine undergoes limited hepatic biotransformation. The primary metabolic pathway is CYP-mediated oxidative deamination producing **para-hydroxyamphetamine** and **phenylacetone**, subsequently oxidised to benzoic acid (excreted as glucuronide and glycine conjugates). Minor pathways produce **N-hydroxyphentermine** and the pharmacologically active metabolite **O-hydroxynorephedrine** (INCHEM [Ref 25]; Skopp & Jantos 2013 [Ref 3]).

**pH-dependence of elimination:** Phentermine is a weak base (pKa ~10.1). Urinary acidification markedly accelerates excretion — at pH 5.5–6.0, approximately 60% of a dose is excreted unchanged within 48 hours. This is pharmacologically significant: co-administration of urinary acidifying agents (ammonium chloride, ascorbic acid) accelerates clearance, while alkalinising agents (sodium bicarbonate, antacids) prolong half-life.

**CYP interactions:** No significant CYP enzyme induction or inhibition has been formally documented for phentermine monotherapy. The compound is not extensively metabolised, limiting metabolic drug-drug interactions [FLAG: no primary human CYP induction/inhibition study identified for phentermine; this is a data gap].

**Formulations:** Phentermine is marketed in two forms: (1) phentermine hydrochloride (Adipex-P: 37.5 mg tablets/capsules; Lomaira: 8 mg tablets) and (2) phentermine resin (Ionamin, now discontinued in the US), which provides slower absorption. The HCl salt is readily water-soluble; the resin form has a markedly extended absorption phase (Skopp & Jantos 2013 [Ref 3]).

---

## History

**Discovery and early development:** Phentermine was first synthesised in the early 20th century as a structural derivative of amphetamine. Unlike amphetamine (with a chiral alpha-methyl group), phentermine introduced a second methyl group at the alpha carbon, creating an achiral structure with reduced dopaminergic activity [Ref 31]. The compound received **FDA approval in 1959** as a short-term anorectic adjunct to caloric restriction [Ref 24].

**Early clinical use:** Throughout the 1960s and 1970s, phentermine was widely prescribed as part of the broader amphetamine-class anorectic era alongside drugs like diethylpropion and benzphetamine. Its Schedule IV classification (enacted with the Controlled Substances Act of 1970) recognised lower abuse potential compared to Schedule II amphetamines.

**The fen-phen era (1992–1997):** The pivotal event in phentermine's history was a 1992 study by Weintraub et al. [Ref 32, 33] that combined phentermine (15 mg) with fenfluramine (60 mg) as adjunctive therapy to diet, exercise, and behaviour modification in 121 obese subjects over 34 weeks. Participants on the combination lost a mean of 14.2 kg (15.9% of body weight) versus 4.6 kg (4.9%) for placebo (p < 0.001). The combination ("fen-phen") became enormously popular: by 1996, **more than 18 million prescriptions** for fen-phen were filled annually in the United States (Connolly et al. 1997 [Ref 34]).

**The fen-phen withdrawal (1997):** In August 1997, Connolly et al. published a landmark report in the *New England Journal of Medicine* [Ref 34] describing valvular heart disease in 24 women who had received fen-phen, with histopathological changes consistent with serotonergic-mediated plaque formation on the leaflets of both left- and right-sided valves; 8 patients also had new pulmonary hypertension. Fenfluramine and dexfenfluramine were voluntarily withdrawn from the US market in September 1997. **Phentermine was not withdrawn**, as pharmacological evidence indicated that fenfluramine (not phentermine) was the causative agent through its serotonergic mechanism [Ref 34].

**Autopsy evidence (fen-phen):** Tomita & Zhao (2002 [Ref 11]) reported autopsy findings of a patient who died of pulmonary hypertension after 7 months of fen-phen: fibroproliferative plaque in pulmonary arteries from main vessels to arterioles, and fibroproliferative tricuspid valve changes.

**European withdrawal (2000–2001):** Following the fen-phen safety concerns, the European Commission adopted decisions in March 2000 requiring EU member states to withdraw all marketing authorisations for anorectic agents including phentermine. The ban became effective April 2001. The European Medicines Agency (EMA) subsequently rejected the phentermine/topiramate combination product (Qsiva) twice (2012, 2013), citing concerns about long-term cardiovascular effects including heart rate elevation [Ref 26].

**Qsymia approval (2012):** On 17 July 2012, the FDA approved phentermine/topiramate extended-release capsules (Qsymia, VIVUS LLC) as an adjunct to lifestyle modification for chronic weight management in adults with BMI ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidities. This was the first new obesity medication approved by the FDA in 13 years. The approval came with a REMS programme due to topiramate's teratogenicity [Ref 36].

**Current status:** As of 2026, phentermine monotherapy remains the **most commonly prescribed obesity medication** in the United States, with decades of real-world use. The LEAP trial (NCT identifier not retrieved; publication 2026 [Ref 15]) represents the first 24-month randomised controlled trial designed to evaluate phentermine's long-term efficacy and cardiovascular safety — a landmark study addressing a critical evidence gap, since the original 1959 approval predated requirements for long-term RCT evidence.

---

## Subjective Effects

Phentermine's subjective effects in clinical and observational contexts are consistent with the profile of a preferential norepinephrine-releasing sympathomimetic agent. Published clinical data, prescribing information, and the atomoxetine abuse liability study (where phentermine served as an active positive control [Ref 45]) indicate the following:

**Established physical effects (from clinical trial adverse event reporting [Ref 18, 19, 24]):**
- **Stimulation / wakefulness:** Described as "overstimulation" and "restlessness" in adverse event terminology; corresponding to CNS activation
- **Appetite suppression:** Primary therapeutic effect; reduced caloric intake via noradrenergic hypothalamic mechanisms
- **Tachycardia / palpitations:** Increased heart rate consistently reported; in adolescent real-world data, increase of 5–10 bpm noted at 9–12 months [Ref 44]
- **Insomnia:** Among the most common adverse events across all clinical trials; late-evening dosing explicitly contraindicated [Ref 24]
- **Dry mouth:** Reported as most common adverse effect in the Weintraub 1992 trial [Ref 32] and subsequent studies
- **Constipation / GI changes:** Reported across trials; occasionally diarrhoea
- **Elevated blood pressure / vasoconstriction:** Sympathomimetic cardiovascular effects

**CNS/cognitive effects (from prescribing information and clinical observations [Ref 24]):**
- Mild mood elevation and increased energy at therapeutic doses
- Potential restlessness, irritability at higher doses
- Headache
- Rare: psychosis, delirium (particularly at supratherapeutic doses or in susceptible individuals)

**Duration of subjective effects:** Given the half-life of 16–31 hours (once-daily dosing), therapeutic plasma levels are maintained continuously during daily use. Acute onset of anorectic and stimulatory effects occurs within 1–4 hours of dosing (corresponding to Tmax of the HCl formulation).

**Tolerance to subjective/therapeutic effects:** Tolerance to the anorectic and stimulant effects develops within weeks of continuous use. The FDA label explicitly states: "A few weeks of drug treatment … Tolerance to the anorectic effect usually develops within a few weeks. When this occurs, the recommended dose should not be exceeded in an attempt to increase the effect; rather, the drug should be discontinued" [Ref 24].

**Effect taxonomy mapping (for generation agent):** Based on published descriptions of therapeutic and adverse effects, the following effects from the PSX taxonomy are supported by published evidence:
- **Body:** stimulation, wakefulness, appetite-suppression, insomnia, dry-mouth, constipation, tachycardia (→ abnormal-heartbeat), vasoconstriction, restlessness, headache, trembling (tremor)
- **Thinking:** focus-enhancement (at therapeutic doses), motivation-enhancement
- **Feeling:** euphoria (mild, at therapeutic doses), anxiety (adverse effect), irritability
- **Self:** disinhibition (mild, at therapeutic/supertherapeutic doses)

---

## Safety & Toxicity

### Acute Toxicity

**Overdose syndrome:** Phentermine overdose produces a sympathomimetic toxidrome characterised by the triad of **hyperactivity, hyperpyrexia, and hypertension** (INCHEM PIM-415 [Ref 25]). Severe overdose can cause:
- CNS: agitation, confusion, hallucinations, delirium, seizures, intracranial haemorrhage, stroke, coma
- Cardiovascular: hypertension, tachycardia, atrial/ventricular arrhythmias, myocardial infarction
- Musculoskeletal: bruxism, trismus, muscle fasciculations, rhabdomyolysis → renal failure, hyperkalaemia
- Death: due to intracranial haemorrhage, acute heart failure, arrhythmia, hyperpyrexia, or rhabdomyolysis-related complications

**LD50:** No human LD50 is established. Animal LD50 data for phentermine were not identified in the literature search. The INCHEM monograph references fatal doses "reported as low as 1.3 mg/kg" but this figure likely derives from amphetamine-class data and is not specific to phentermine — **FLAG for editorial review: this value is unverified for phentermine specifically and should not be published without a primary source.**

**Blood concentration variability:** Signs of toxicity can appear at blood concentrations of ~20 µg/L, while chronic users have survived concentrations up to 3,000 µg/L (INCHEM [Ref 25]; reflecting developed tolerance in amphetamine-class users — species applicability unclear).

**Fatal overdose in population data:** Hall, Korona-Bailey & Mukhopadhyay (2023 [Ref 35]) identified phentermine's presence in toxicology reports from fatal drug overdoses in Tennessee (2019–2022), establishing a real-world mortality signal. In most fatal cases, phentermine was identified alongside other substances, consistent with polydrug overdose rather than phentermine monodrug lethality.

**Overdose management:** Treatment is primarily supportive — airway/breathing/circulation stabilisation, monitoring of cardiac rhythm and temperature, control of seizures and agitation, treatment of hyperthermia, management of rhabdomyolysis. Urinary acidification accelerates phentermine excretion (INCHEM [Ref 25]; FDA label [Ref 24]).

### Cardiovascular Adverse Events

- **Pulmonary hypertension (monotherapy):** A Korean case report describes a 29-year-old woman developing pulmonary hypertension (PA pressure 56 mmHg, right ventricular dilatation) after just 5 weeks of phentermine monotherapy — described as the first reported case of phentermine-alone PPH (Bang et al. 2010 [Ref 8]).
- **Valvular disease with fen-phen:** Histopathologically documented in autopsy (Tomita & Zhao 2002 [Ref 11]) and in echocardiographic surveillance (Connolly et al. 1997 [Ref 34]). The causative agent was fenfluramine (serotonergic mechanism), not phentermine.
- **FAERS analysis:** FDA adverse event reporting system analysis (Gorelik et al. 2020 [Ref 9]) evaluated cardiovascular safety signals for currently marketed anti-obesity drugs including phentermine.
- **Cardiovascular contraindications:** Phentermine is absolutely contraindicated in coronary artery disease, stroke, arrhythmia, heart failure, and uncontrolled hypertension [Ref 24].

### Psychiatric Adverse Events

Case reports associating phentermine with severe psychiatric outcomes (hypertension, mental illness) are documented by Skopp & Jantos 2013 [Ref 3]. The FDA label lists psychosis as a rare CNS adverse effect [Ref 24]. A 2025 case report describes multi-organ serotonin syndrome with antiobesity + antidepressant drug combination [Ref 38].

---

## Harm Reduction

### Contraindications (from FDA prescribing information [Ref 24])

**Absolute contraindications:**
1. Concurrent or recent use (within 14 days) of monoamine oxidase inhibitors (MAOIs) — risk of **hypertensive crisis**
2. History of cardiovascular disease (coronary artery disease, stroke, arrhythmias, heart failure, uncontrolled hypertension)
3. Hyperthyroidism
4. Glaucoma
5. Agitated states
6. History of drug abuse
7. Pregnancy (teratogenicity risk from combined phentermine/topiramate formulations; topiramate is a known teratogen) [Ref 36]
8. Nursing
9. Known hypersensitivity to sympathomimetic amines

### Drug Interactions

| Interaction | Risk | Mechanism |
|---|---|---|
| MAOIs | ABSOLUTE CONTRAINDICATION | Hypertensive crisis; excessive catecholamine release |
| SSRIs/SNRIs | Potential serotonin syndrome | Additive serotonergic activity; risk low with monitoring [Ref 37] |
| Insulin / oral hypoglycaemics | Dose adjustment needed | Phentermine-induced weight loss alters insulin requirements |
| Adrenergic blockers | Reduced antihypertensive effect | Phentermine antagonises alpha/beta blockade |
| Alcohol | Enhanced adverse CNS effects | Additive CNS stimulant + depressant interaction |
| Urinary acidifiers (ammonium chloride) | Increased phentermine clearance | pH-dependent renal excretion accelerated |
| Urinary alkalinisers (sodium bicarbonate) | Prolonged phentermine half-life | pH-dependent renal excretion decreased |

**Serotonin syndrome with SSRIs:** Although theoretically concerning, a survey of 1,174 patients taking phentermine with SSRIs found zero cases of serotonin syndrome; monitored combination use is considered justifiable by bariatric medicine practitioners (Rader et al. 2008 [Ref 37]). However, a 2025 case report documents serotonin syndrome with multi-organ injury from antiobesity + antidepressant combination [Ref 38]. Clinical monitoring is warranted.

### Testing and Identification

Phentermine can be detected in urine (2–4 days post-dose at standard doses), serum, and hair. Gas chromatography following derivatisation was historically used; LC-MS/MS is now preferred for biological specimen analysis (Skopp & Jantos 2013 [Ref 3]). Phentermine will yield **positive results on amphetamine immunoassay urine drug screens** — users should disclose prescription to testing facilities.

### Emergency Response

For phentermine overdose: call Poison Control (US: 1-800-222-1222). Supportive care, benzodiazepines for agitation/seizures, cooling for hyperthermia, IV fluids for rhabdomyolysis. Urinary acidification can accelerate elimination. Avoid beta-blockers alone (may worsen hypertension via unopposed alpha stimulation).

---

## Tolerance & Dependence

### Tolerance

Tolerance to phentermine's anorectic and stimulant effects develops within **a few weeks** of continuous use. The FDA label explicitly states that when tolerance develops, the dose should **not** be increased, and the drug should be discontinued rather than escalated [Ref 24]. In the Weintraub 1992 fen-phen study, some tolerance to the combination was also documented over the 4-year study period [Ref 33].

### Dependence and Abuse Potential

**Schedule IV classification** (DEA, US; CDSA Schedule IV, Canada) indicates recognised but relatively low abuse potential compared to Schedule II amphetamines.

**Withdrawal on abrupt cessation (Hendricks & Greenway 2011 [Ref 13]):** In a study of 35 patients who abruptly stopped long-term phentermine, scores on the modified Kampman Cocaine Selective Severity Assessment were not significantly different from drug-naive controls. There was a "striking and significant difference" between phentermine-treated subjects and amphetamine-dependent subjects. Cravings — the hallmark of substance dependence — were **entirely absent** in phentermine-treated subjects. Conclusion: abrupt cessation does not induce amphetamine-like withdrawal; symptoms after stopping represent loss of therapeutic effect, not withdrawal.

**Long-term addiction potential (Hendricks et al. 2014 [Ref 12]):** A larger study specifically investigating whether long-term phentermine treatment induces abuse, psychological dependence, or drug craving in obese patients, also with assessment of amphetamine-like withdrawal. [NOTE: The abstract did not report outcomes — findings not extracted; this paper should be retrieved for full text.]

**Abuse liability as positive control (Jasinski et al. 2008 [Ref 45]):** Phentermine was used as a stimulant positive control alongside methylphenidate in an abuse liability study of atomoxetine in stimulant-preferring drug abusers, confirming it produces stimulant-like subjective effects recognisable to drug users — but at a lower level than prototypical stimulants.

**Cross-tolerance:** Structural similarity to amphetamine suggests probable cross-tolerance with other catecholamine-releasing agents (amphetamine, methamphetamine, MDMA), though direct cross-tolerance studies were not identified. This is an unresolved evidence gap.

---

## Interactions

(See also Harm Reduction section for interaction table)

**MAOI interaction (absolute contraindication):** MAOIs inhibit the enzymatic degradation of released norepinephrine and dopamine. Phentermine-induced NE release combined with MAO inhibition can produce a potentially fatal hypertensive crisis or serotonergic hyperstimulation [Ref 24].

**Other stimulants:** Co-administration with other monoamine releasing agents (amphetamine, MDMA, cocaine) would be expected to produce additive or synergistic sympathomimetic toxicity. No published interaction studies identified for these combinations — **FLAG: data gap.**

**CNS depressants / alcohol:** The FDA label warns of potential adverse reactions with alcohol. The interaction mechanism is complex (stimulant counters sedation but can mask intoxication, increasing injury risk).

**Fenfluramine (historical):** The fen-phen combination amplified weight loss through synergistic noradrenergic (phentermine) + serotonergic (fenfluramine) mechanisms. Phentermine coadministration did not significantly potentiate fenfluramine-induced serotonin depletion in mouse brain at far above-human doses (Baumann et al. 1996 [Ref 14]).

**Insulin/hypoglycaemics:** Phentermine-induced weight loss reduces insulin resistance; dose reduction of antidiabetic agents may be needed to prevent hypoglycaemia [Ref 24].

**Cardiovascular drug interactions (CONQUER subanalysis [Ref 22]):** In hypertensive patients receiving PHEN/TPM ER in the CONQUER trial, systolic blood pressure was reduced by 7.5–11.8 mmHg (p<0.001 vs <5% weight loss group), suggesting that weight-loss-mediated BP reduction may require adjustment of antihypertensive medications.

---

## Legal Status

| Jurisdiction | Status | Notes |
|---|---|---|
| United States | Schedule IV controlled substance (DEA) | FDA-approved 1959; prescription required; phentermine monotherapy and Qsymia (PHEN/TPM) both approved |
| Canada | Schedule IV (CDSA) | Available by prescription |
| Australia | Approved (TGA) | Marketed as Duromine (phentermine resin capsules); prescription required |
| New Zealand | Approved | Available as Duromine |
| United Kingdom | Withdrawn | MHRA withdrew marketing authorisation ca. 2000 |
| European Union | Banned | European Commission March 2000 decision; ban effective April 2001 |
| Germany | Withdrawn | Cited in Skopp & Jantos 2013 [Ref 3] |
| Sweden, Turkey, Venezuela | Banned | [Ref 26, web sources] |

**REMS (USA):** The Qsymia (PHEN/TPM ER) formulation carries a mandatory Risk Evaluation and Mitigation Strategy (REMS) to prevent pregnancy exposure due to topiramate's teratogenicity. Phentermine monotherapy does not have a REMS requirement [Ref 36].

**Drug testing:** Phentermine will cause a positive result on standard amphetamine immunoassay urine drug screens. Confirmatory GC-MS or LC-MS/MS testing is required to distinguish phentermine from methamphetamine/amphetamine [Ref 3].

---

## Clinical Trials

### Phentermine Monotherapy

| NCT | Title | Status | Phase | Key Findings |
|---|---|---|---|---|
| N/A (LEAP) | Long-Term Effectiveness of Anti-Obesity Medication Phentermine (LEAP) | Active/Ongoing (2026) | Phase 3 RCT | 24-month double-blind RCT; first-ever long-term RCT for phentermine monotherapy [Ref 15] |
| NCT01719185 | Phentermine and B12 on Weight Loss in Obese Patients | Completed | Early Phase 1 | Phentermine + vitamin B12 combination |
| NCT03675191 | Orlistat/Phentermine Versus Placebo/Phentermine | Completed | N/A | Gangnam Severance Hospital combination study |

### Phentermine/Topiramate (Qsymia) Pivotal Trials

| NCT | Title | Key Result | Status |
|---|---|---|---|
| NCT00554216 (EQUIP) | PHEN/TPM CR in severely obese adults | 15/92 mg: −10.9% vs −1.6% placebo at 56 weeks; 66.7% achieved ≥5% weight loss [Ref 18] | Completed Phase 3 |
| NCT00553787 (CONQUER) | PHEN/TPM CR in overweight/obese with ≥2 risk factors | Significant weight loss vs placebo; improvements in lipids, BP, glucose [Ref 19] | Completed Phase 3 |
| NCT00796367 (SEQUEL) | 2-year extension of CONQUER | Sustained weight loss at 108 weeks: −10.5% (15/92 mg) vs −1.8% placebo [Ref 20] | Completed Phase 3 |
| NCT02243202 | Canagliflozin 300 mg + Phentermine 15 mg | Phase 2; combination with SGLT2 inhibitor | Completed Phase 2 |
| NCT02659475 | PHEN/TPM in Binge Eating Disorder | Phase 2; novel indication | Completed Phase 2 |
| NCT04721873 | Phentermine as adjunct in Ulcerative Colitis with Obesity | Novel inflammatory indication | Recruiting Phase 2 |

### Paediatric Trials

| Study | NCT | Key Result |
|---|---|---|
| Kelly et al. 2022 (NEJM Evidence) | NCT not retrieved | 56-week RCT, adolescents 12–17 y: 15/92 mg → −7.1% BMI vs +3.3% placebo [Ref 39] |
| PHEN/TPM adolescent predictors (Bensignor 2025) | NCT not retrieved | Baseline characteristics predicting BMI response in adolescents [Ref from search] |

---

## Community Feedback Analysis

No community feedback was submitted in Part A2 of the brief.

---

## Gaps & Flags

### Data Gaps

1. **CYP enzyme profile:** No published human study of CYP induction or inhibition by phentermine identified. The INCHEM monograph describes metabolic pathways but does not specify which CYP isoforms are responsible. This gap is relevant to drug-drug interaction assessment. **FLAG: generation agent should note absence of definitive CYP interaction data.**

2. **Long-term monotherapy RCT:** As of the LEAP trial design publication (2026), no completed 24-month randomised trial of phentermine monotherapy has been published. All long-term weight loss data for phentermine monotherapy are from observational studies or real-world analyses. **FLAG: the LEAP trial (NCT unknown) is actively ongoing; generation agent should note this is the first-ever long-term RCT for phentermine monotherapy.**

3. **Specific LD50 for phentermine:** No human LD50 data and no verified animal LD50 specifically for phentermine identified in the literature. INCHEM references low fatal doses but these likely derive from amphetamine-class estimates, not phentermine-specific data. **FLAG: do not publish any LD50 figure for phentermine without a verified primary source.**

4. **Full CONQUER trial efficacy data:** The CONQUER abstract retrieved from PubMed did not include the specific percentage weight loss data point (the web summary cited 12.4% at 15/92 mg). **FLAG: verify the CONQUER maximum dose weight loss figure against the full paper text before publishing.**

5. **Binding affinity data (Ki values):** The Rothman 2001 data provides EC₅₀ values for release; no Ki values for transporter binding (as opposed to release) were identified for phentermine. The EC₅₀ values quoted above are for efflux of pre-loaded [³H]monoamines from synaptosomes — a functional release measure, not a binding affinity measure.

6. **Dose-duration structure:** The brief requested dose and duration data. Published clinical trial data supports:
   - *Therapeutic dose range:* 8 mg tid (Lomaira) or 15–37.5 mg/day (Adipex-P)
   - *Duration:* Traditionally labelled short-term (≤12 weeks); increasingly used long-term in clinical practice; 56-week and 108-week data exist for PHEN/TPM combination
   - No specific published controlled data on duration-of-effect for individual doses (e.g., onset/offset in hours) was found for phentermine monotherapy in humans — pharmacokinetic estimates suggest 6–12 hour pharmacodynamic effect duration based on Tmax and half-life context.

7. **Addiction potential study full data:** The Hendricks et al. 2014 paper (PMID 23736363) on long-term addiction potential retrieved only the abstract with aims, not results. Full-text access is recommended.

8. **Synthesis history:** No primary academic literature identifying the original chemist or synthesis date for phentermine was found. It is known to have been synthesised before 1959 (FDA approval), likely as part of the amphetamine chemical family explorations of the 1930s–1950s, but a primary source for the original synthesis paper was not identified. **FLAG: date and author of original synthesis unverified.**

9. **Psychoactive characterisation discrepancy:** The brief characterises phentermine as "emerging," which is inconsistent with its status as an FDA-approved drug since 1959 with decades of clinical data. This is almost certainly a database artefact — **FLAG for editorial correction of the characterisation field.**

10. **Cross-tolerance data:** No published studies on cross-tolerance between phentermine and other stimulants (amphetamine, MDMA, methylphenidate) were identified. Cross-tolerance is presumed based on shared mechanism but not verified.

### Safety-Critical Flags

- **MAOI contraindication:** Absolute; hypertensive crisis risk. Confirmed by FDA label [Ref 24].
- **Pregnancy:** Absolute contraindication for PHEN/TPM (teratogenic due to topiramate component). Phentermine monotherapy in pregnancy — no controlled data; presumed unsafe. **FLAG: generation agent should clearly state contraindication without attributing teratogenicity solely to phentermine.**
- **Pulmonary hypertension risk:** Reported with monotherapy (Bang 2010 [Ref 8]) and combination (Connolly 1997 [Ref 34]). Risk level quantification for monotherapy is not established from controlled data.
- **Cardiovascular contraindication:** All patients with established cardiovascular disease, uncontrolled hypertension, or arrhythmias should not use phentermine [Ref 24].